<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Isaac Ekundayo, MD on Medium]]></title>
        <description><![CDATA[Stories by Isaac Ekundayo, MD on Medium]]></description>
        <link>https://medium.com/@isaacekundayo?source=rss-48914a38ef9a------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*hIBUzM5Xze3O40IdIGcSGA.jpeg</url>
            <title>Stories by Isaac Ekundayo, MD on Medium</title>
            <link>https://medium.com/@isaacekundayo?source=rss-48914a38ef9a------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 13:49:51 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@isaacekundayo/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Subsaharan-Africa’s $100B HealthTech Opportunity: A Deep Dive into the Startups Powering the Future…]]></title>
            <link>https://medium.com/included-vc/subsaharan-africas-100b-healthtech-opportunity-a-deep-dive-into-the-startups-powering-the-future-d73051670c72?source=rss-48914a38ef9a------2</link>
            <guid isPermaLink="false">https://medium.com/p/d73051670c72</guid>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Isaac Ekundayo, MD]]></dc:creator>
            <pubDate>Mon, 23 Mar 2026 11:23:13 GMT</pubDate>
            <atom:updated>2026-03-23T11:23:13.449Z</atom:updated>
            <content:encoded><![CDATA[<h3>Subsaharan-Africa’s $100B HealthTech Opportunity: A Deep Dive into the Startups Powering the Future of Care</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wVCeglik5KO2v2iWAouetw.png" /></figure><h3>1. Executive Summary</h3><h3>Key Insights at a Glance</h3><p>This report is the culmination of an exhaustive research engagement involving the sourcing, categorization, and analysis of over <a href="https://docs.google.com/spreadsheets/d/1dVvVPBADyuMWYpXFBgwY9mG1xTeRDhTrqLqer0pDwsk/edit?usp=sharing"><strong>430 active HealthTech startups across Sub-Saharan Africa</strong></a>. The synthesis of this proprietary dataset, combined with deep-dive market intelligence from East, West and South Africa, reveals a sector in the midst of a profound structural transition.</p><p>We are witnessing the end of the “Pilot Era”, characterized by fragmented, donor-funded experiments, and the dawn of the “Infrastructure Phase.” The winners emerging from this ecosystem are not merely building apps; they are constructing the digital and physical rails of a<a href="https://www.meer.com/en/99427-africas-health-boom-the-business-of-being-sick"> <strong>$100 billion healthcare economy</strong></a><strong>.</strong> The data indicates a decisive pivot from Business-to-Consumer (B2C) telemedicine, which struggles with unit economics in a low-trust, out-of-pocket market, toward Business-to-Business (B2B) and Business-to-Government (B2G) models that digitize the supply chain, finance, and operational backbones of the sector.</p><p>While Nigeria, Kenya, and South Africa remain the dominant hubs for capital deployment, our analysis highlights a “Flight to Quality” in deal flow. Investors are concentrating capital into fewer, later-stage scale-ups that demonstrate clear paths to profitability or strategic acquisition. Furthermore, “Proof of Concept” markets like Rwanda are leveraging state-led innovation to validate models that are then exported, while the Francophone region, often overlooked due to language barriers and regulatory rigidity, represents a massive, untapped arbitrage opportunity for patient capital.</p><h3>Market Size &amp; Growth Signals</h3><p>The African healthcare market is<a href="https://healthcap.co/bridging-the-funding-gap-a-case-for-private-investment-in-african-healthcare/"> projected to reach<strong> $259 billion by 2030</strong></a>. Within this, the HealthTech-specific opportunity is valued conservatively at $100 billion, a figure derived not just from care delivery, but from the unaddressed inefficiencies in supply chain logistics, counterfeit drug prevention, and health financing gaps.</p><ul><li><strong>Resilient Deal Flow:</strong> Despite global macroeconomic headwinds that have frozen capital markets elsewhere, healthcare dealmaking in Africa has shown remarkable resilience. Analysis of recent transaction data indicates that average deal values have risen four-fold since 2023. This is not a bubble; it is a correction towards viability. The market is shifting away from pre-seed scattergun bets toward Series A and B rounds for companies with proven unit economics.</li><li><strong>Startup Density &amp; Survival:</strong> Our tracking of 430+ entities reveals a high mortality rate at the pre-seed stage, often termed the “Grantpreneur Trap”, but a robust and growing cohort of “Camel” startups (built for sustainability) in the growth phase. Nigeria leads in sheer volume of activity, Kenya dominates in digital integration and private equity interest, and South Africa leads in high-value medical device regulation and adoption.</li><li><strong>Strategic Validation:</strong> The exit landscape is maturing. We are observing a marked increase in strategic acquisitions by global conglomerates, such as <a href="https://www.cfaogroup.com/en/cfao-healthcare-acquires-100-of-goodlife-pharmacy/"><strong>CFAO’s acquisition of Goodlife Pharmacy</strong></a> and <a href="https://femtechinsider.com/sanofi-invests-in-kasha/"><strong>Sanofi’s strategic investment in Kasha</strong></a><strong>. </strong>These events validate the hypothesis that African HealthTechs are building assets of global strategic value, particularly in their ability to reach the “last mile” consumer.</li></ul><h3>Investment Thesis</h3><p>The prevailing investment thesis for the next decade has shifted fundamentally from “Access” (connecting a patient to a doctor via video) to “Enablement” (empowering the existing offline system with digital tools). The highest risk-adjusted returns are currently found in three verticals:</p><ol><li><strong>Asset-Light Supply Chain:</strong> Companies that are digitizing the fragmented network of patent medicine vendors and pharmacies (e.g., Maisha Meds, mPharma), effectively becoming the operating system for retail health.</li><li><strong>Embedded FinTech:</strong> Platforms that do not sell “health” directly but integrate credit, inventory financing, and micro-insurance into the workflow of clinics and pharmacies (e.g., Reliance HMO, Turaco).</li><li><strong>Specialized B2B SaaS:</strong> Solutions solving specific, high-friction administrative problems for hospitals and diagnostic labs, where the willingness to pay is established and churn is low (e.g., Helium Health).</li></ol><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*UKb017bsHmCa_tArAsE5kQ.png" /></figure><h3>2. What is HealthTech (in the African Context)?</h3><h4>Defining HealthTech &amp; Its Relevance in Africa</h4><p>To understand the opportunity, one must first strip away Western definitions of “HealthTech.” In Silicon Valley or Europe, the term often conjures images of frontier technologies: CRISPR genomics, AI-driven drug discovery, or robotic surgery assistants. In Sub-Saharan Africa, the definition is grounded in <strong>Frugal Innovation</strong> and <strong>System Strengthening</strong>.</p><p>Here, HealthTech is the application of technology to bridge massive, existential infrastructure gaps. It is the answer to a continent with a physician-to-patient ratio of 1:10,000 in many regions; a supply chain where 30% of drugs may be counterfeit; and a financing landscape where <a href="https://www.researchgate.net/publication/370776764_Healthcare_Financing_in_Nigeria_A_Policy_Review#:~:text=An%20adoptive%20narrative%20review%20of,changing%20but%20highly%20unequal%20society."><strong>97% of the population lacks formal insurance</strong></a>.</p><p>In this context, a “HealthTech” company is just as likely to be a logistics fleet moving blood on motorbikes (LifeBank) as it is to be a software company. The relevance of the sector lies in its ability to leapfrog. Just as Africa bypassed landline telephony for mobile, HealthTech offers the potential to bypass the “heavy infrastructure” phase of healthcare development, moving straight to decentralized, mobile-first, data-driven care delivery.</p><p>Key categories defining this landscape include:</p><ul><li><strong>Tech-Enabled Logistics:</strong> Moving physical goods (blood, oxygen, vaccines) with the precision of e-commerce to prevent stock-outs.</li><li><strong>Digital Triage &amp; Telephony:</strong> Utilizing USSD, SMS, and chatbots to provide triage to populations without smartphones or 4G data.</li><li><strong>Financing Rails:</strong> Building the digital wallets and micro-insurance, and claims switches that allow money to move in a friction-heavy economy.</li></ul><h3>How it Differs from Global Markets</h3><p>The “Patient Journey” in Africa bears little resemblance to that in the Global North, necessitating a fundamentally different tech stack and business model.</p><ul><li><strong>Infrastructure Dependence:</strong> Western digital health apps assume a baseline of continuous electricity and high-speed broadband. African HealthTechs must be architected as “offline-first.” Data must sync asynchronously; devices must have long-life batteries or solar backups; and software must be lightweight enough to run on low-end Android devices.</li><li><strong>Trust Mechanics:</strong> In global markets, trust is institutional — placed in the hospital brand or the regulatory body. In Africa, trust is hyper-local and relational. A patient trusts their neighborhood pharmacist or community nurse, not a faceless app. Consequently, successful startups do not try to disintermediate these human nodes; they co-opt them, empowering the local chemist with a tablet rather than trying to replace them with a website.</li><li><strong>Payment Models:</strong> The US market is driven by complex reimbursement codes and third-party payers. African HealthTech operates in a brutal cash economy where 75%+ of transactions are out-of-pocket. This forces startups to innovate on business models — introducing pre-payment wallets, employer-deducted subscriptions, or diasporan remittance models — to unlock revenue.</li></ul><blockquote><strong>Just as Africa bypassed landline telephony for mobile, HealthTech offers the potential to bypass the “heavy infrastructure” phase of healthcare development, moving straight to decentralized, mobile-first, data-driven care delivery. — Isaac Ekundayo, MD</strong></blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bfJtBXCV1cyeHe8eb6QdnA.png" /></figure><h3>3. Macro Trends Shaping HealthTech in Africa</h3><h3>Demographic &amp; Epidemiological Drivers</h3><p>The sheer scale of demand is the primary driver. With a population exceeding 1.5 billion and a median age of 19, Africa is the future of the global labor force. However, this demographic dividend is threatened by a unique “Double Burden” of disease:</p><ol><li><strong>Persistent Infectious Diseases:</strong> Malaria, Tuberculosis, and HIV/AIDS remain significant public health challenges requiring massive, tech-enabled supply chain management for testing and treatment.</li><li><strong>The Rise of NCDs:</strong> Non-Communicable Diseases (diabetes, hypertension, oncology) now account for approximately 37% of deaths in the region. This transition is critical for HealthTech because NCDs cannot be “cured” with a single pill; they must be <em>managed</em> over decades. This shifts the need from episodic care to longitudinal data tracking, creating a structural, long-term demand for Electronic Medical Records (EMRs), remote monitoring devices, and continuity-of-care platforms.</li></ol><h3>Digital Infrastructure Expansion</h3><p>The bedrock of the current HealthTech boom is the ubiquity of mobile money. Ten years ago, collecting a $2 micro-insurance premium was logistically impossible; the cost of cash collection exceeded the value. Today, rails like <strong>M-Pesa </strong>(Kenya), <strong>MTN Mobile Money</strong> (West Africa), and <strong>Wave </strong>(Francophone Africa) allow for seamless, near-zero-cost transactions. Coupled with smartphone penetration that is projected to hit 65% in markets like Senegal and Cote d’Ivoire by 2025, the addressable market for rich-interface health applications is expanding beyond the urban elite to the peri-urban mass market.</p><h3>Policy &amp; Regulatory Shifts</h3><p>After years of lagging behind innovation, governments are moving from passivity to active, albeit fragmented, regulation.</p><ul><li><strong>Harmonization Efforts:</strong> The operationalization of the African Medicines Agency (AMA) and the harmonization initiatives within the East African Community (EAC) are attempting to create a unified regulatory framework. This is vital for hardware and pharmaceutical startups, which currently face the nightmare of registering products in 54 separate jurisdictions.</li><li><strong>Data Sovereignty:</strong> Countries like Rwanda (2019) and Kenya (2021) have enacted strict Data Protection Acts. While these protect citizens, they also impose compliance burdens, forcing startups to localize servers and implement rigorous data governance — a barrier to entry that favors established, well-capitalized players over scrappy upstarts.</li></ul><h3>COVID-19 Acceleration Effects</h3><p>The pandemic acted as a powerful forcing function for the sector. Practically, it forced regulators to greenlight telemedicine, which had previously existed in a legal gray area. Strategically, it exposed the fragility of global supply chains, shattering the illusion that Africa could rely solely on imports for medical security. This has sparked a renewed, government-backed interest in local manufacturing of medical devices, PPE, and diagnostics, creating a new sub-sector of “Hard Tech” innovation previously considered too risky for VC investment.</p><h3>4. HealthTech Sector Breakdown</h3><p>Our analysis of the <a href="https://docs.google.com/spreadsheets/d/1dVvVPBADyuMWYpXFBgwY9mG1xTeRDhTrqLqer0pDwsk/edit?usp=sharing"><strong>430+ startups sourced for this report </strong></a>allows for a granular segmentation of the ecosystem. The sector is far broader than the “Doctor-on-Demand” apps that dominate headlines.</p><h3>4.1. Consumer Health &amp; Wellness</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lYNi-kXnqjeuOMdzyJb3jw.png" /></figure><p>This segment focuses on the direct-to-consumer (D2C) interaction, though it is rapidly evolving toward B2B2C models due to customer acquisition costs.</p><ul><li><strong>Telemedicine 2.0:</strong> First-wave players offered simple video calls. Current leaders like <a href="https://nigeria.zuri.health/"><strong>Zuri Health</strong></a> (Kenya), <a href="https://tibu.africa/"><strong>Tibu Health</strong></a> (Kenya), and <a href="https://web.facebook.com/DoctorNowNG/?_rdc=1&amp;_rdr#"><strong>DoctorNow</strong></a> (Ghana) have pivoted to “Hybrid Care.” They realized that purely virtual care has a ceiling in a market requiring physical diagnostics. These platforms now integrate home visits (nurses on motorbikes), sample collection, and physical clinic partnerships into an omni-channel offering.</li><li><strong>Mental Health &amp; Wellness:</strong> Startups like <a href="https://www.wazi.co/"><strong>Wazi</strong></a> (Kenya) and <a href="https://nguvuhealth.com/"><strong>Nguvu Health</strong></a> (Nigeria) are addressing the silent epidemic of mental health. Given the stigma and low willingness to pay, these companies often monetize via B2B employer wellness plans rather than direct consumer subscriptions.</li><li><strong>Fitness:</strong> Apps like <strong>Sixpackfactory</strong> target the emerging middle class, but remain a niche compared to clinical services.</li></ul><h3>4.2. Clinical Operations &amp; Hospital Tech</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*G1izhea-mrNfudZZyOE5lw.png" /></figure><p>This is the “Operating System” layer of African healthcare — a B2B SaaS play with high retention.</p><ul><li><strong>EMR &amp; Data:</strong> <strong>Helium Health</strong> (Nigeria/Regional) is the market leader, having digitized hundreds of hospitals. Their strategy is not just software fees; it is data leverage. By seeing the cash flow of a hospital, they can underwrite loans (HeliumCredit) for facility expansion, solving a massive credit gap. <strong>Afya Rekod</strong> (Kenya) takes a patient-centric approach, aiming to give the patient ownership of their portable health record.</li><li><strong>Workflow Automation:</strong> Startups like <strong>Keragon</strong> and <strong>Healthstack</strong> focus on specific friction points , automating staff scheduling, insurance claims generation, and inventory ordering to reduce the crushing administrative overhead of understaffed facilities.</li></ul><h3>4.3. Diagnostics &amp; Labs</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*nSgHGU0CEWGBtHFSfjYywA.png" /></figure><p>Access to diagnostics is a major bottleneck; most small clinics lack the capital to buy ultrasound or X-ray machines.</p><ul><li><strong>Asset-Light Diagnostics:</strong> <strong>Ilara Health</strong> (Kenya) and <strong>MDaaS Global</strong> (Nigeria) have disrupted this space with a “lease-to-own” or revenue-share model. They equip peri-urban clinics with compact diagnostic devices, sharing the revenue from tests run. This decentralizes care, bringing diagnostics closer to the patient and capturing value from the high-volume/low-margin segment.</li><li><strong>AI Imaging:</strong> <strong>Neural Labs Africa</strong> and <strong>Insightiv</strong> (Rwanda) use AI algorithms to screen X-rays for Tuberculosis and Pneumonia. In a region with a severe shortage of radiologists, this “AI Triage” acts as a force multiplier, allowing human specialists to focus only on pathological cases.</li></ul><h3>4.4. Health Financing &amp; Insurance Tech</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4jRFAkEbVIdbFKeaW7LkRw.png" /></figure><p>With insurance penetration in single digits, tech is trying to solve the affordability crisis.</p><ul><li><strong>Claims Automation:</strong> <strong>Curacel</strong> (Nigeria) and <strong>Smart Applications</strong> (Kenya) are the “Visa/Mastercard” of health claims. They use AI to detect fraud and automate approvals between providers and insurers. This reduces the administrative cost of insurance, theoretically allowing premiums to drop.</li><li><strong>Micro-Insurance:</strong> <strong>Turaco</strong> (Kenya), <strong>WellHealth</strong> (Nigeria) and <strong>Reliance HMO</strong> (Nigeria) are rethinking distribution. They bundle health insurance with airtime, ride-sharing gigs, or loans. By embedding insurance into products people already buy, they bypass the difficult direct sale of insurance.</li></ul><h3>4.5. MedTech &amp; IoT Devices</h3><p>This is the “Hard Tech” frontier, strongest in East Africa where engineering talent from universities like Makerere is clustering.</p><ul><li><strong>Frugal Hardware:</strong> <strong>Wekebere</strong> (Uganda) designs fetal monitors specifically for rural clinics — rugged, battery-operated, and connected to mobile apps for data analysis. <strong>Neopenda</strong> produces wearables for newborn vital sign monitoring in overcrowded wards.</li><li><strong>Point-of-Care:</strong> <strong>Vula Mobile</strong> (South Africa) connects primary healthcare workers directly to specialists via an app, facilitating referrals and advice that prevent unnecessary hospital journeys.</li></ul><h3>4.6. Pharmaceuticals &amp; Supply Chain Tech</h3><p>The most capital-intensive but potentially lucrative segment, addressing the broken distribution of drugs.</p><ul><li><strong>Vendor Managed Inventory (VMI):</strong> <strong>mPharma</strong> (Ghana/Regional), <strong>Lifestores Healthcare</strong> (Nigeria), and <strong>Maisha Meds</strong> (Kenya) have revolutionized this space. They take over the inventory risk for independent pharmacies, ensuring stock availability and quality. In exchange, they capture margin and data.</li><li><strong>Anti-Counterfeit:</strong> <strong>Chekkit</strong> and <strong>RxAll</strong> deploy blockchain tracking and handheld chemical scanners to verify drug authenticity at the point of sale, restoring trust in a market where fake drugs are a lethal problem.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*rssrrVryNtKpE6W0kFh-XA.png" /></figure><h3>5. Ecosystem Players</h3><h3>5.1. Startups by Segment &amp; Stage</h3><p>Analyzing the 430+ startups reveals a distinct “Pyramid” structure in the ecosystem, highlighting both the vibrancy of early-stage innovation and the brutality of the growth phase.</p><p><strong>The Base: Pre-Seed &amp; Seed (The “Pilot” Zone)</strong></p><ul><li><strong>Volume:</strong> The vast majority of entities (approx. 70%) reside here.</li><li><strong>Characteristics:</strong> High mortality rate. Many are “Grantpreneurs” — ventures kept alive by donor funding rather than commercial revenue. They often struggle with product-market fit and operational scaling.</li><li><strong>Examples:</strong> <em>Waspito</em> (Cameroon), <em>Klarah</em> (Cameroon), <em>Preggify</em> (Nigeria), <em>Huruma Connect</em> (Kenya).</li></ul><p><strong>The Middle: Series A &amp; Growth (The “Validation” Zone)</strong></p><ul><li><strong>Volume:</strong> A thinning layer (approx. 20%) that has survived the “Valley of Death.”</li><li><strong>Characteristics:</strong> Proven unit economics. These companies have typically pivoted from B2C to B2B/B2B2C models and are expanding geographically. They are attracting commercial VC but still face challenges in raising larger ticket sizes ($10M+).</li><li><strong>Examples:</strong> <em>Ilara Health</em>, <em>Remedial Health</em>, <em>Turaco</em>, <em>DrugStoc</em>.</li></ul><p><strong>The Peak: Scale-Ups &amp; Exits (The “Consolidators”)</strong></p><ul><li><strong>Volume:</strong> A select handful (&lt;10%).</li><li><strong>Characteristics:</strong> Vertically integrated, operating in multiple countries, and capable of acquiring smaller players. They are the primary targets for global strategic acquirers or PE firms.</li><li><strong>Examples:</strong> <em>Helium Health</em>, <em>mPharma</em>, <em>Goodlife Pharmacy</em> (Acquired by CFAO), <em>Zipline</em> (Unicorn status).</li></ul><p><strong>Key Ecosystem Insight:</strong> The “Missing Middle” remains acute. Startups that cannot transition their DNA from “social enterprise” to “venture-backable business” typically stall at the seed stage. The ecosystem needs more bridge capital (mezzanine debt) to help hardware and supply chain companies graduate to Series A.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*QiK_0qhihikau2isG5imCg.png" /></figure><h3>6. Capital Flows &amp; Investment Dynamics</h3><h3>Funding by Stage, Segment &amp; Geography</h3><p>This section analyzes <em>where</em> the money is actually going, versus the hype.</p><ul><li><strong>Pre-Seed/Seed:</strong> This stage is heavily dominated by <strong>Impact Capital</strong> and <strong>Grants</strong> (Gates Foundation, Google for Startups, Villgro Africa). There is a critical reliance on “catalytic capital” to de-risk the initial infrastructure build-out. Commercial angels are present but risk-averse regarding hardware.</li><li><strong>Series A+:</strong> The landscape shifts to Pan-African VCs (Partech, TLcom, Ventures Platform) and specialized Health funds (HealthCap, LeapFrog Investments). Capital at this stage is highly concentrated in <strong>FinTech-Enabled Health</strong> (e.g., Reliance, Helium) and <strong>Supply Chain</strong> (mPharma). Pure clinical delivery plays (hospitals/clinics) struggle to raise VC money due to asset heaviness and lower margins.</li></ul><h3>Geography &amp; The “Halo Effect”</h3><ul><li><strong>The Big Four Dominance:</strong> Nigeria, Kenya, South Africa, and Egypt capture &gt;80% of HealthTech funding. This concentration creates a self-reinforcing cycle where infrastructure and talent cluster in Lagos, Nairobi, Cape Town, and Cairo.</li><li><strong>The Expat/Diaspora Bias:</strong> Data analysis confirms a “Halo Effect.” Startups founded by expatriates or African diaspora with degrees from Western institutions (Harvard, Stanford, Oxford) attract a disproportionate share of VC capital. In Kenya and Uganda, this “expat bubble” is particularly visible. These founders “speak the language” of global investors, have access to networks, and understand the metrics VCs want to see. Conversely, local founders often struggle to raise beyond the seed stage, forced to rely on bootstrapping or grants. This creates a “capital apartheid” where the best-funded companies are not always the most locally integrated or culturally competent.</li><li><strong>The Francophone Gap:</strong> Despite political stability and economic growth in countries like Cote d’Ivoire and Senegal, the region receives less than 5% of tech funding. This is a massive arbitrage opportunity. Valuation multiples are lower, and competition is scarcer, but investors are deterred by the language barrier and perceived regulatory rigidity.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*uN4lPIXEYZ37krbmu9jPLA.png" /></figure><h3>Insight: Over-Concentrated vs. Underserved</h3><ul><li><strong>Over-Concentrated Capital:</strong> B2C Telemedicine apps in urban Lagos and Nairobi. The CAC is too high, retention is too low, and the market is saturated with copycat models.</li><li><strong>Underserved Segments:</strong></li><li><strong>Mezzanine/Working Capital Debt:</strong> Supply chain and hardware startups need debt to buy inventory or components. They don’t need expensive equity for this; they need debt. Yet, local banks demand 20%+ interest and 100% collateral. There is a massive gap for debt funds.</li><li><strong>Local Manufacturing:</strong> Producing Class A/B medical devices (syringes, gloves, basic diagnostics) locally. This is capital intensive but offers long-term defensive moats against currency devaluation and import shocks.</li></ul><h3>7. Unit Economics &amp; Business Model Viability</h3><h3>The Fallacy of B2C Pay-Per-Use</h3><p>Early HealthTech 1.0 startups (circa 2015–2018) often failed because they attempted to copy Western “Uber for X” models. They assumed patients would pay $5-$10 for a video consultation. They were wrong.</p><ul><li><strong>Reality Check:</strong> The average African consumer has low disposable income and views healthcare as a “grudge purchase” — an emergency expense, not a subscription lifestyle.</li><li><strong>The Math:</strong> Customer Acquisition Costs (CAC) via Facebook/Google ads often exceeded the Lifetime Value (LTV) because retention was near zero. Patients would use the app once for an emergency and never return, or bypass the app to see the doctor directly next time.</li></ul><h3>The Winning Models: B2B, B2B2C, and Aggregation</h3><p>To survive, startups have pivoted to models that secure revenue from entities with budgets, not cash-strapped individuals.</p><ul><li><strong>B2B SaaS (The “Sticky” Model):</strong> Selling to hospitals (e.g., Helium Health) or pharmacies (e.g., Maisha Meds). Once a facility digitizes its records or inventory, the switching costs are incredibly high. This creates low churn and predictable recurring revenue.</li><li><strong>Aggregation (The “WellaHealth” Model):</strong> Instead of selling malaria insurance to individuals one by one (high CAC), WellaHealth aggregates micro-insurance plans and sells them to insurers or corporates for their staff. They then fulfill the service through a network of local pharmacies. This B2B2C approach drastically lowers CAC and leverages existing trust networks.</li><li><strong>B2G (Business to Government):</strong> High risk, high reward. In state-dominated markets like Rwanda, the government is the only payer that matters. Startups like <strong>Zipline</strong> succeeded by securing national-level service contracts. However, for most startups, B2G is a trap due to long sales cycles (18–24 months), political risk, and unreliable payment terms.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*UKb017bsHmCa_tArAsE5kQ.png" /></figure><h3>Who Actually Pays?</h3><p>Sustainable models have successfully shifted the payer burden:</p><ul><li><strong>Insurers:</strong> Paying tech partners to detect fraud or reduce claim costs.</li><li><strong>Employers:</strong> Paying for staff wellness plans to reduce absenteeism.</li><li><strong>Pharma/Market Intelligence:</strong> Paying for anonymized data on consumption patterns (e.g., Maisha Meds monetizing data insights).</li><li><strong>Donors:</strong> Subsidizing the cost of tech to achieve public health goals (e.g., Gates Foundation funding supply chain visibility tools).</li></ul><h3>8. Regulatory &amp; Market Access Reality Check</h3><h3>Execution Friction: The Silent Killer</h3><p>Policy announcements (like “Digital Health Strategies”) often mask the brutal reality of execution friction on the ground.</p><ul><li><strong>Medical Device Registration:</strong> Most countries lack a mature framework for evaluating locally made devices. Regulators like the <strong>Pharmacy and Poisons Board (PPB)</strong> in Kenya or <strong>NAFDAC</strong> in Nigeria often default to demanding “US FDA Approval” or “CE Mark” as a prerequisite for registration. For a seed-stage African startup, obtaining FDA approval is prohibitively expensive and time-consuming. This regulatory laziness stifles local hardware innovation.</li><li><strong>The E-Pharmacy Ban:</strong> In Francophone Africa (Cote d’Ivoire, Senegal, Burkina Faso), the law remains protectionist. Regulations explicitly forbid the online sale of medicine and the advertising of pharmaceuticals. This effectively kills the “Amazon for Drugs” B2C model. Startups in this region are forced into B2B models — providing “digital inventory tools” to pharmacies rather than selling to patients — to avoid being shut down.</li></ul><h3>9. Go-to-Market &amp; Distribution Patterns</h3><h3>Distribution is the Moat</h3><p>In Africa, technology is not the moat; distribution is. You cannot simply launch an app and expect adoption. You need “boots on the ground” and integration into the physical world.</p><p><strong>1. The Pharmacy as the Hub</strong> Pharmacies and Patent Medicine Vendors (PMVs) are the primary point of care for 80% of patients. They are trusted, accessible, and ubiquitous. Successful startups like <strong>mPharma</strong>, <strong>Lifestores</strong>, and <strong>WellaHealth</strong> do not try to bypass the pharmacy; they co-opt it. They brand the pharmacy, power its backend, and use it as a fulfillment center.</p><p><strong>2. Agent Networks &amp; Trust Proxies</strong> Startups cannot buy trust; they must borrow it.</p><ul><li><strong>Human Agents:</strong> <strong>Turaco</strong> sells insurance through agents who are already selling airtime or loans. <strong>Maziwa</strong> (breastfeeding pumps) uses “community breastfeeding ambassadors” to drive adoption because online retail is insufficient.</li><li><strong>Telco Integration:</strong> Leveraging the brand of MTN or Safaricom validates the service in the eyes of the consumer.</li></ul><p><strong>3. The “Offline-First” Imperative</strong> Founders consistently rank “Offline-First” functionality as a critical growth lever. Apps must work via USSD or SMS (e.g., <strong>MobiCure</strong>’s Omomi). Field apps for agents must allow data entry without internet, synchronizing only when connectivity returns. Pure cloud solutions fail in peri-urban and rural markets.</p><h3>10. Talent, Founders &amp; Team Composition</h3><h3>The Talent Gap</h3><p>While the entrepreneurial spirit is abundant, specific technical skills are in severe shortage.</p><ul><li><strong>Biomedical Engineers:</strong> Rwanda produces only ~30 MSc graduates in Biomedical Engineering per year. Kenya has only two universities offering full degrees. This lack of human capital severely limits the ability to design, maintain, or manufacture medical hardware locally, forcing startups to manufacture in China or rely on expensive expat talent.</li><li><strong>Data Scientists:</strong> Top local talent is aggressively poached by FinTechs (who pay better) or global remote roles.</li></ul><h3>Education &amp; Capacity Building</h3><p>Initiatives like <a href="https://x.com/MedintechAfrica"><strong>Medintech Africa</strong></a> are emerging to bridge this gap. By training thousands of students in “Applied Digital Health,” they are creating a pipeline of future founders and operators who understand both the clinical and technical sides of the equation.</p><h3>11. Interoperability &amp; Infrastructure Readiness</h3><h3>The Data Island Problem</h3><p>Interoperability is the “unsexy” barrier to scale. African healthcare runs on islands of data — paper records, Excel sheets, or proprietary legacy systems that don’t talk to each other. There is no unified “Patient ID” (like a Social Security Number for health).</p><ul><li><strong>The Consequence:</strong> Referrals are manual. Insurance claims are slow. Public health surveillance is fragmented.</li><li><strong>The Solution:</strong> Startups like <strong>Helium Health</strong> and <strong>Afya Rekod</strong> are racing to become the interoperability layer. By capturing the primary data at the facility level, they hope to build the “Health Information Exchange” of the future.</li></ul><h3>The “Infrastructure Tax”</h3><p>Digital health businesses in Africa pay a tax that their global peers do not: the cost of physical infrastructure.</p><ul><li><strong>Power:</strong> Hospitals face frequent blackouts. Startups must often provide solar inverters or batteries just to keep their software running on client sites.</li><li><strong>Connectivity:</strong> Cloud-only architectures are fragile. Local server/edge computing solutions are often required to ensure continuity of service.</li></ul><h3>12. Outcomes &amp; Impact Measurement</h3><p>For Development Finance Institutions (DFIs) and Impact Investors, the metric of success is not just Annual Recurring Revenue (ARR), but lives touched and systems strengthened.</p><ul><li><strong>Clinical Impact:</strong> <strong>LifeBank</strong> tracks metrics like “minutes to delivery” and claims to have saved over 20,000 lives by delivering blood on time.</li><li><strong>System Efficiency:</strong> <strong>Maisha Meds</strong> tracks not just sales, but protocol adherence — using software nudges to ensure pharmacists dispense the <em>correct</em> malaria treatment, thereby improving clinical outcomes and reducing drug resistance.</li><li><strong>Cost Savings:</strong> <strong>mPharma</strong>’s “Mutti” program aggregates demand to lower the cost of drugs for patients, a measurable economic impact that validates their model to donors and governments.</li></ul><h3>13. Failure Modes &amp; Market Gaps (Extremely Valuable)</h3><h3>Why HealthTech Startups Fail in Sub-Saharan Africa</h3><p>Honest analysis of “deadpooled” startups (like <strong>EMedrep</strong> and various anonymous telemedicine ventures) reveals recurring patterns of failure:</p><ol><li><strong>Grantpreneurship:</strong> Startups that design their product to win grants, not to solve user problems. They survive from grant to grant in “Perpetual Pilot Mode” and collapse when the donor focus shifts because they never built a commercial revenue engine.</li><li><strong>Overbuilding Tech, Underbuilding Trust:</strong> Launching a sleek, Silicon-Valley-style telemedicine app without a network of trusted physical clinics. Patients will not pay a stranger on a phone.</li><li><strong>Regulatory Blindness:</strong> Ignoring the power of incumbents (Pharmacist Councils, Medical Boards). EMedrep struggled because its capital structure was misaligned with the slow pace of market adoption and regulatory friction.</li><li><strong>Capital Misalignment:</strong> Taking high-velocity VC money for a hardware or logistics play that requires “patient capital.” Hardware iterates slower than software; VC timelines often force premature scaling, leading to cash crunches.</li></ol><h3>Unmet Needs &amp; White Spaces</h3><ul><li><strong>Mezzanine Debt:</strong> There is a desperate need for working capital debt for pharmacies and clinics to buy inventory and equipment. Equity is too expensive; banks won’t lend. A specialized debt fund for health SMEs is a massive white space.</li><li><strong>Local Manufacturing of Consumables:</strong> While complex devices are hard, producing simple consumables (gloves, syringes, basic tubing) locally is viable and necessary to reduce the 90% import reliance.</li><li><strong>Francophone B2B Enablers:</strong> Since direct sales are banned, there is a massive opportunity for B2B platforms to digitally connect the <em>existing</em> pharmacy network in Francophone Africa without violating retail laws.</li></ul><h3>14. Competitive Landscape vs Global HealthTech</h3><ul><li><strong>vs. India:</strong> India shares a fragmented market structure but has a massive advantage: a robust local pharmaceutical and device manufacturing base and a deep pool of technical talent. African startups are more reliant on imports and often face higher talent costs relative to revenue.</li><li><strong>vs. Global:</strong> African HealthTech is “Full Stack.” A US startup might just build the booking software (ZocDoc). An African startup (e.g., <strong>CarePoint</strong>) often has to buy the clinics, train the doctors, manage the supply chain, <em>and</em> build the software to ensure quality. This makes them operationally heavier but potentially more defensible against purely digital competitors.</li><li><strong>Leapfrogging:</strong> Just as the continent leapfrogged landlines, African hospitals are bypassing the “Server Room” era. They are moving straight to cloud-native, mobile-first EMRs. There is less “tech debt” to undo in the public sector compared to the US or Europe.</li></ul><h3>15. Strategic Outlook (5–10 Year Horizon)</h3><h3>The Next Decade</h3><ul><li><strong>Consolidation:</strong> The market cannot support 50 different EMRs or telemedicine apps. We will see regional winners (like Helium Health or mPharma) acquiring smaller local players to capture geography and market share.</li><li><strong>Integration with Public Health:</strong> The ultimate scale lies in integrating with National Health Insurance Schemes (NHIS). Startups that become the “operating system” for the public sector will win. Those that remain outside the public system will remain niche.</li><li><strong>The Rise of “Payvidors”:</strong> HealthTechs will increasingly become insurers (Payers) + Providers. Controlling the full money loop — collecting the premium and managing the care — is the only way to guarantee margins and quality.</li><li><strong>AI as a Force Multiplier:</strong> Not for flashy robotic surgeries, but for <strong>Task-Shifting</strong>. AI will enable a nurse in rural Kenya to interpret an ultrasound or an ECG that previously required a specialist, radically expanding access to specialized care.</li></ul><p><strong>Report Methodology Note:</strong> This report leverages proprietary data from over 430 startups extracted from the provided research datasets , integrated with deep-dive qualitative reports on the East African ecosystem , Nigerian market dynamics , Francophone regulatory landscapes , and investment outlooks. The synthesis aims to provide an operational reality check beyond the high-level investment narratives often found in public media.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d73051670c72" width="1" height="1" alt=""><hr><p><a href="https://medium.com/included-vc/subsaharan-africas-100b-healthtech-opportunity-a-deep-dive-into-the-startups-powering-the-future-d73051670c72">Subsaharan-Africa’s $100B HealthTech Opportunity: A Deep Dive into the Startups Powering the Future…</a> was originally published in <a href="https://medium.com/included-vc">Included VC</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How the America First Global Health Strategy Shapes Africa’s Health Technology Ecosystem]]></title>
            <link>https://medium.com/included-vc/how-the-america-first-global-health-strategy-shapes-africas-health-technology-ecosystem-5f5793734d6b?source=rss-48914a38ef9a------2</link>
            <guid isPermaLink="false">https://medium.com/p/5f5793734d6b</guid>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Isaac Ekundayo, MD]]></dc:creator>
            <pubDate>Mon, 12 Jan 2026 09:02:56 GMT</pubDate>
            <atom:updated>2026-01-26T11:37:11.656Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fyq1w5Pa2ts0UoplD5vAXw.png" /></figure><h3>A. When Global Health Sounds Like a Business Plan</h3><p>I first read the <a href="https://ng.usembassy.gov/america-first-global-health-strategy/"><strong>America First Global Health Strategy (AFGHS)</strong></a><strong> </strong>back in September 2025, and I had to stop for a moment.</p><p>As I went through it, I couldn’t help but wonder: <em>is this a health strategy or a venture capitalist memo?</em> It didn’t sound like any policy brief I’d read before.</p><p>Normally, you’d expect familiar themes: aid effectiveness, global solidarity, multilateral cooperation. But this document spoke a different language entirely: <em>co-investments, sovereign guarantees, private-sector leadership.</em> Words like <em>de-risking, commercial partnerships, bilateral compacts</em> filled the pages.</p><p>And that shift in language matters. Words aren’t just words; they shape how policy is made and how power is exercised. When Washington starts talking about <em>investment</em> instead of <em>aid</em>, the incentives change. The power dynamics change.</p><p>At its core, what’s happening here is a reframing: the U.S. is redefining its global health engagement around its own strategic interests: making America safer, stronger, and more prosperous. Health programs are no longer just about helping countries; they’re now aligning aid with commercial and geopolitical objectives.</p><p>That makes sense from the US’ perspective, but for African countries, where donor priorities have long shaped national health plans, this isn’t just another policy. It’s a new set of rules: who benefits, who sets the terms, and ultimately, who wins?</p><p>As <a href="https://www.linkedin.com/in/isaac-ekundayo/">someone</a> who has built, pitched, and sometimes painfully pivoted within Africa’s health-tech ecosystem, I read the AFGHS and saw two things at once:</p><ul><li>A pipeline of new potential demand: African health innovators and startups suddenly find themselves in conversations, contracts, and spaces that were previously inaccessible.</li><li>A threat that the continent’s health needs would be reframed to serve other countries’ commercial priorities.</li></ul><h3>B. From Altruism to Advantage</h3><p>The AFGHS’s practical implications fall into three broad transitions: <strong>bilateralism over multilateralism</strong>, <strong>private-sector primacy over NGOs</strong>, and <strong>investment framing over philanthropy</strong>.</p><p>Bilateral compacts promise speed and direct accountability. For decades, U.S. health funding flowed through organizations like <a href="https://www.who.int/">WHO</a>, the <a href="https://www.theglobalfund.org/">Global Fund</a>, and <a href="https://www.gavi.org/">Gavi</a>. That system had a safety net: pooled risk, technical standards, and layers of oversight.</p><p>But the new strategy favours direct agreements with countries.</p><p>That sounds efficient, right? Faster money, fewer bureaucratic hoops.</p><p>But it also gives the US more direct leverage over recipient governments. In a world where political alignment matters, bilateralism deals aren’t just deals. They are tests. Can countries negotiate from a position of strength, or will they just sign what’s offered?</p><p>The second shift is institutional. Where NGOs once played the central role of implementation partners, the AFGHS signals an explicit tilt toward <strong>American companies and investors</strong> as primary co-implementers.</p><p>In practice this means procurement, contracting, and market access may increasingly privilege U.S. firms.</p><p>For entrepreneurs and civil society groups across Africa, that poses a question: will the ecosystem be opened to local innovators, or will guaranteed contracts favor multinational incumbents?</p><p>Third is the language of <strong>aid as investment</strong>. The AFGHS expects recipient countries to co-invest and progressively assume financing responsibilities. That is not inherently wrong; sustainable country ownership is an important objective.</p><p>But the devil is in the design.</p><p>When co-investment is required without realistic financing pathways, poorer countries become policy-takers rather than equal partners. And when donor capital is used as a way to de-risk American private capital, aid becomes a channel for commercial advantage, not only public health.</p><p><strong>A Nairobi policymaker </strong>put it plainly when I asked what mattered most: “We welcome efficiency, but efficiency for whom?” That question is everything. Because efficiency without fairness, local ownership, or control over resources doesn’t solve Africa’s challenges. It just shifts the advantage to whoever holds the money.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/756/1*Q_ZSRkPP6deyYr2fa-KMNw.jpeg" /><figcaption><strong>Engaging policy makers and entrepreneurs at the 5th Africa Digital Health Summit, Lagos, Nigeria</strong></figcaption></figure><h3><strong>C</strong>. The Investment Shockwave</h3><p>Think about it like this: if policy is the script, money is the actor. Follow the capital, and you see how incentives reshape behaviour.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*reCnoGjhIlV_ctJaGwVjoA.png" /></figure><p>In 2024, African startups raised roughly <strong>US$2.2 billion in equity</strong>. That number makes headlines and is used to benchmark the continent’s tech momentum. But that headline masks sectoral imbalances: fintech continued to dominate deal flow and attention, while health tech captured a relatively small share. <a href="https://partechpartners.com/africa-reports/2024-africa-tech-venture-capital-report">Partech’s 2024 report</a> and other ecosystem trackers show that while the total funding pool is meaningful, health tech remained a minority slice of the pie; investors chased consumer fintech and climate tech with greater enthusiasm.</p><p>Why did fintech win so much capital? Two reasons: regulatory clarity and unit economics. Interoperable systems like BVN (in Nigeria, for example) and mobile money rails created straightforward customer acquisition and revenue models. Health tech, by contrast, is fragmented, heavily regulated, and depends on institutional buyers. It has historically relied on grants, donor procurement, and long procurement cycles. That complexity makes investors hesitant.</p><p>Enter AFGHS, which promises to convert public health demand into <strong>sovereign-backed, predictable revenue</strong>, precisely the signal private investors crave. Bilateral procurement guarantees, performance-linked payments, and co-investment frameworks make health contracts more bankable. <a href="https://www.avca.africa/media/pk1lhhzc/avca_2024_venture_capital_in_africa_report_rel-31-march.pdf?utm_source=chatgpt.com"><strong>Development finance institutions</strong></a> already report a growing appetite for blended finance models that combine public guarantees and private capital to fund medical manufacturing and diagnostics capacity in Africa. That shift has the capacity to turn health tech from a donor-subsidized experiment into a viable asset class.</p><p>But of course, there’s a flip side. When public procurement becomes the primary demand engine, early-stage companies must meet complex regulatory and operational expectations quickly, capabilities that many nascent founders lack. There is also a risk that procurement rules will favour large, experienced foreign vendors able to meet compliance and delivery terms, effectively crowding out local innovators. <a href="https://www.linkedin.com/in/fewagod/"><strong>Sheriff Alimi</strong></a><strong> of </strong><a href="https://www.venturesplatform.com/"><strong>Ventures Platform</strong></a> summarized the dilemma: <em>“We might gain access to new funding, but we must define our terms. Otherwise, we risk trading our autonomy for short-term capital.”</em></p><p>So the AFGHS is both a shock and an opportunity. For investors, it derisks. For founders and governments, it requires new skills: contract negotiation, quality assurance, and local value capture. How Africa organizes itself will determine whether the continent lands on the ascending or descending side of that shockwave.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Tzep8HvBo8I_lrht_8rlpw.jpeg" /><figcaption><em>Source: </em><a href="https://partechpartners.com/africa-reports/2024-africa-tech-venture-capital-report"><em>Partech 2024 report</em></a></figcaption></figure><h3>D. Founders on the Frontline</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/768/1*_z_17iPzhpoPMQ9XMlWlFA.jpeg" /><figcaption><strong>With Dr. Funmi Adewara, CEO and Founder, </strong><a href="https://www.mobihealthinternational.com/"><strong>Mobi Health</strong></a></figcaption></figure><p>Talk to African founders, and you hear everything: excitement, exhaustion, and a sense of urgency all tangled together.</p><p><a href="https://www.linkedin.com/in/chiji-ndukauba?originalSubdomain=ng"><strong>Chiji Ndukauba</strong></a><strong>, manager at </strong><a href="https://heliumhealth.com/"><strong>Helium Health,</strong></a> described the reality in blunt terms: “We’re suddenly part of conversations we were excluded from two years ago. U.S. programs are asking for pilots. But they want anonymized, standards-compliant datasets, and we simply don’t have them.” His point is straightforward: data readiness has become the price for participation.</p><p>In Kigali, I met a founder who had just been disqualified from a government tender because her company did not meet a foreign vendor’s bank guarantee requirement. “They prefer vendors who can show global procurement experience,” she told me. “We have product-market fit, but not the procurement bureaucracy muscle.” That tension is familiar: market need exists, but the system keeps the doors half-closed.</p><p>Many founders are pragmatic. <a href="https://www.linkedin.com/in/irene-nwaukwa/?originalSubdomain=ng"><strong>Irene Nwaukwa</strong></a><strong>, CEO of </strong><a href="https://www.infinityhealth.africa/"><strong>Infinity Health Africa</strong></a><strong> and a former </strong><a href="https://techpoint.africa/news/54gene-founder-breaks-silence-on-resignation/"><strong>54Gene</strong></a><strong> executive</strong>, argues for pragmatic hybridization: use local startups for implementation, reserve foreign partners for highly specialized roles, and make skill transfer mandatory. “If partnerships don’t include training and IP sharing,” she says, “then we get the work but not the capability.”</p><p>The deeper issue founders face is timing. Grant cycles historically funded proof-of-concept. Now, commercial contracts require scale, compliance, and formal systems. And that gap: the space between pilot-ready and procurement-ready, is where so many startups get stuck.</p><p>Without patient capital, technical assistance, and local procurement reform, the pipeline linking African ingenuity to bilateral contracts will clog.</p><p>Still, I think there’s hope. Digital health platforms that standardize anonymized data can position African firms as indispensable partners. The same goes for companies building regulatory-grade manufacturing, quality-controlled diagnostics, or telemedicine infrastructure. But here’s the truth: the founders who adapt fast and the systems that back them will be the ones to define what African health tech looks like in this next chapter.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/700/1*M19ImbhRqTBCc7K1rWaXKw.jpeg" /><figcaption><strong><em>Source: Baobab insights.</em></strong></figcaption></figure><h3>E. The Investors’ Pivot</h3><p>DFIs, family offices, and global VCs are quietly reworking their playbooks in response to the new incentives.</p><p>You see, when the U.S. signs bilateral health deals backed by government guarantees and performance-linked payments, it’s basically sending a signal: this space is safe now. Suddenly, health investments that used to look risky now look like safe bets. DFIs love that. It gives them a reason to bring in more private capital without losing sleep over uncertainty.</p><p>And it’s already showing up in the data. UNCTAD and other trackers have been recording a steady rise in private investments flowing into Africa’s pharmaceutical and medical manufacturing sectors. Some of that is because of domestic policy improvements, but much of it comes from blended-finance setups that combine public money with private risk-taking.</p><p>Philanthropy is also repositioning itself as catalytic capital. <a href="https://www.gatesfoundation.org/ideas/articles/2024-gates-foundation-annual-letter">The Gates Foundation’s 2024 strategy</a>, for instance, set aside billions for targeted interventions that act as early-stage shock absorbers.</p><p>The idea? Philanthropy takes the first hit, clears the path, and then steps aside so private markets can move in and scale solutions.</p><p>That approach aligns neatly with AFGHS’s framing: philanthropy fills gaps so private investors can buy in later.</p><p>Yet investors and DFIs are raising the same questions founders and policymakers are asking: who sets the terms? If public money is used to underwrite private profits without mechanisms for local value retention (no jobs, no IP, no manufacturing capacity), then what’s really happening is this: Africa’s health problems are being turned into investment opportunities for others.</p><p>That’s why this investor pivot feels double-edged. On one hand, it could unlock the capital Africa needs for industrialization and health innovation. On the other, it could leave us with foreign firms owning the profits while local players just execute contracts.</p><p>The policy architecture — local content conditions, shared IP, and skills transfer — will determine whether the investment pivot becomes an engine for inclusive growth or a thin layer of foreign supply chains on top of local needs.</p><p>So, the real question here isn’t whether investment is coming. It’s what kind of investment and on whose terms. The rules written into these deals about local content, shared IP, and skill transfer will decide whether this new wave of capital builds Africa’s capacity or just builds someone else’s balance sheet.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fdvFJO2eio7yaVuhOpQVdA.png" /><figcaption><strong>VCs investing in African Health Technology Startups</strong></figcaption></figure><h3>F. Policymakers: Ready in Policy, Weak in Practice</h3><p>Across Africa, there’s genuine eagerness to engage with this new wave of global health investment. You can feel it in the speeches, the strategy documents, and the national roadmaps. But when it comes to translating that enthusiasm into execution, the cracks start to show.</p><p>Several countries now have health technology strategies and digital health roadmaps on paper. But financing remains the bottleneck. The UNCTAD and national budget analysis show that most African countries still fall short of the Abuja target of 15% of national budgets earmarked for health; only a small number meet or exceed it. That fiscal constraint affects everything: procurement, workforce capacity, infrastructure, and even how fast a country can match donor or bilateral co-financing terms.</p><p>Now, implementation looks very different from country to country. Rwanda has built a relatively sophisticated digital governance architecture and has been proactive about attracting partnerships that fit its national priorities. Kenya continues to iterate on Afya (health) reforms to coordinate donor programs. Nigeria’s complex federal structure makes harmonized procurement and national rollouts more challenging. These differences matter. A nation with an integrated health data architecture and agile procurement can negotiate bilateral compacts from a position of strength, while a nation without those capabilities will be negotiating from scarcity.</p><p>Let’s break that down with a few examples:</p><p>• <strong>Rwanda</strong>: The government’s digital investments and centralized health governance have made it an attractive partner for pilots and health systems modernization. Its ability to integrate donor programs into a national digital backbone gives it comparative leverage. (Local observers and founders report preferential partnering with Rwandan startups that can plug into national systems.)</p><p>• <strong>Kenya</strong>: Kenya’s regulatory environment and digital entrepreneurship ecosystem are robust in certain domains. However, procurement complexity and subnational fragmentation sometimes slow bilateral execution.</p><p>• <strong>Nigeria</strong>: Nigeria’s scale is a strength and a liability. Federal-state complexities, budget cycles, and procurement opacity mean co-investment pledges are often hard to deploy quickly. Startups face a patchwork of rules that complicate national scale.</p><p><strong>One Ghanaian official</strong> told me, “We’re negotiating bilateral compacts with the U.S., but co-financing remains a challenge. Our budget cycle simply doesn’t move as fast as theirs.” That single line captures the biggest risk of the America First Global Health Strategy: when your ambition outpaces your administrative and fiscal muscle, dependency takes on a new shape.</p><p>African policymakers are not blind to these tradeoffs. They want to negotiate compacts that include local value provisions and agreements that truly empower domestic innovation and build capacity. But the critical question is whether they have the systems, resources, and enforcement power to make those provisions stick at scale and at speed. That’s where good policy meets hard reality, and that’s where the real test begins.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/768/1*IQDwXfJBxr-BeAzFQ7TNgA.jpeg" /><figcaption><strong>Policy Internship with the Clinton Health Access Initiative during the heat of the USAID funding freeze in March</strong></figcaption></figure><h3>G. NGOs in Transition</h3><p>Non-governmental organizations find themselves repurposing roles.</p><p>For decades NGOs were the agile backbone of health delivery, especially in community outreach, vaccination drives, and HIV programs. Under the AFGHS model that routes funds directly to governments and private implementers, NGOs no longer automatically sit at the center of implementation. That shift affects communities and local trust networks.</p><p>Many NGOs are already adapting by becoming conveners, incubators, and capacity builders. Amref, PATH, and others are investing in accelerator programs, technical assistance, and training, trying to ensure that local innovators are procurement-ready. Instead of being frontline implementers in all contexts, NGOs increasingly act as brokers between communities, startups, and governments.</p><p>But this transition isn’t uniform. Where NGOs pull back too quickly, service gaps appear, particularly in maternal, newborn, and child health programs that rely heavily on community networks. The real challenge is balancing reinvention with continuity: how do you pivot to new roles without leaving essential services behind?</p><p>NGOs that successfully pivot will likely be those that maintain strong local partnerships, focus on skills transfer, and leverage their convening power to protect community health functions during systems transitions. If they fail, the human cost could be high.</p><h3>H. The Data Question: Power in Pixels</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*KG6nPznXz79lJGktdxv_2Q.png" /></figure><p>If money is the lifeblood of this shift, data is the nervous system, and Africa must urgently decide who controls it.</p><p>AFGHS emphasizes interoperable digital systems accessible to U.S. and partner governments. While interoperability can enhance surveillance and clinical care, it raises thorny questions around <strong>data sovereignty, IP rights, and algorithmic benefit sharing</strong>.</p><p>Across Africa the legal terrain is mixed. In recent years there has been a surge in data protection laws. <a href="https://yellowcard.io/blog/the-state-of-data-protection-laws-in-africa-2024/">Some trackers</a> show more than two-thirds of countries with privacy legislation, while others note around 38–39 nations had laws by early 2024. This reflects rapid but uneven progress. The nuance is enforcement: law on paper is different from robust regulatory infrastructure that can govern cross-border data agreements and ensure local benefits.</p><p><strong>Picture this scenario</strong>: an African health ministry signs a bilateral compact that funds a U.S. company to deploy a malaria analytics platform. The platform aggregates anonymized patient records, trains proprietary AI models, and then the company commercializes predictive analytics globally. Did Africa benefit beyond the initial contract? Did local researchers gain access, or is the value (trained algorithms, IP, commercial products) owned by the foreign firm?</p><p>To avoid such outcomes, Africa can take lessons from both the European GDPR playbook and the Indian digital public goods model. Practical measures include:</p><ul><li><strong>Local data storage requirements</strong> for patient-level records;</li><li><strong>Joint IP arrangements</strong> where AI models trained on African data are co-owned or licensed on fair terms;</li><li><strong>Transparent data-sharing agreements</strong> with enforceable benefit-sharing clauses;</li><li><strong>Regional interoperability standards</strong> that protect data while enabling utility for public health.</li></ul><p>Without these safeguards, Africa risks becoming the raw data supplier for technologies it does not own. And that comes with long-term consequences for scientific capacity, economic value capture, and digital sovereignty.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fwTE7wqj3CIRQF1TyUepSA.png" /><figcaption><strong>Market Map for Healthtech Companies</strong></figcaption></figure><h3>I. The Geopolitical Chessboard</h3><p>Viewed from a wider angle, AFGHS is a chess move in a geopolitical game.</p><p>China’s investment footprint in African health infrastructure has expanded dramatically in recent decades: hospitals, medical equipment, and vaccine plant investments figure into Beijing’s engagement strategy. <a href="https://www.rand.org/content/dam/rand/pubs/research_reports/RRA4100/RRA4151-1/RAND_RRA4151-1.pdf">RAND</a> and other analyses document thousands of Chinese health projects across Africa in the past two decades. That footprint changed expectations about what external partners can and will deliver.</p><p>The U.S. response, via AFGHS, is not simply health policy; it is a geopolitical counterweight aiming to reassert influence through commercial partnerships and bilateral compacts. That competition can produce better deals for African governments when they play the two sides wisely. But it can also force countries into accepting agreements that don’t align with long-term industrial policies or local priorities.</p><p>The strategic prize for African governments is to avoid binary choices. Rather than selecting a single foreign partner, the continent should aim for a complementary approach: using Chinese capital for infrastructure, American partnerships for technology and market access, and homegrown innovation for local delivery.</p><p>That multipolar approach can leverage competition to extract the best terms, provided Africa negotiates collectively and confidently.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ulnZsKzhIekfKNnAOiAR_A.png" /></figure><h3>J. The African Playbook: Turning Policy into Power</h3><p>So, how should African governments, founders, and funders really respond? The answer is a practical, multi-layered playbook that helps turn external strategies into domestic wins:</p><ol><li><strong>Negotiate local value.<br></strong>Every bilateral compact should mandate local content, tech transfer, and shared IP frameworks. Contracts without these clauses are giveaways.</li><li><strong>Develop co-funding capacity.<br></strong>Create budgetary mechanisms such as contingency lines, health innovation funds, and first-loss domestic capital that allow governments to move quickly when co-investment is required.</li><li><strong>Coordinate regionally.<br></strong>Harmonize procurement and data policies through AUDA-NEPAD, Africa CDC, and regional economic communities. Bargaining together increases leverage and reduces duplication.</li><li><strong>Build blended-finance models.<br></strong>Combine domestic first-loss capital with DFI guarantees and philanthropic catalytic capital to de-risk local startups and manufacturing projects.</li><li><strong>Elevate startup diplomacy.<br></strong>Create formal channels for founders to engage ministries like healthtech councils, regulatory sandboxes, and industry roundtables that give entrepreneurs a seat at the negotiation table.</li><li><strong>Invest in data governance and digital public goods.<br></strong>Prioritize interoperable national health data systems, clear data protection and IP frameworks, and open datasets that enable local innovation without compromising privacy.</li></ol><p>These steps are not rocket science. They are a mix of political will, pragmatic finance design, and capacity building. But they are urgent. Without them, the structural asymmetries embedded within AFGHS will calcify into persistent inequities.</p><p><strong>A founder of a Nigeria pharma supply chain health tech company</strong> I really admire said it perfectly: “African innovators must stop waiting for Western validation. We know what works for our markets. The future belongs to those who build inward.”</p><p>That inward building, local manufacturing, locally governed data, and fairer contracts are how Africa can turn an externally led strategy into a springboard for domestic opportunity.</p><h3>K. From Dependency to Design Power</h3><p>When I co-founded <a href="https://x.com/MedintechAfrica"><strong>Medintech Africa</strong></a>, the scaffolding of our ambitions was simple: teach, build, test, repeat. We relied on small grants and volunteer energy. Aid was not an ideology — it was survival. Today the rules of the game have shifted: aid is investment; investment is influence.</p><p>This moment is a test of African agency. If we accept the new rules passively, we become a testing ground. If we respond strategically, we become architects.</p><p>Imagine this instead: a <strong>Pan-African Digital Health Compact</strong>, a regional framework negotiated by AU institutions that sets minimum standards for local content, shared IP, data sovereignty, and procurement reciprocity. Imagine blended-finance facilities that provide bridge capital for startups transitioning from grant pilots to procurement readiness. Imagine a marketplace where African startups compete for national and regional contracts on even terms, backed by domestic co-investment and technical assistance.</p><p>That is not utopian. It is policy work: legislative reform, regional coordination, and investment in institutions. It requires donors to accept a different framing: support that strengthens public systems and local industry rather than carving out preferential market share for foreign vendors. It also requires African governments to make hard choices like allocating domestic funds, reforming procurement, and insisting on fair terms.</p><p>If Africa seizes this window, the continent can convert a Washington-led strategy into a springboard for domestic capability. If it doesn’t, it risks replaying the old story: foreign capital arrives, projects launch, local ecosystems remain underdeveloped, and the long arc of ownership stays out of reach.</p><p>I do not believe Africa will choose passivity. Across universities, startups, and ministries there is a sense of urgency and invention. The question is coordination: can we turn scattered capacity into coherent bargaining power?</p><p>Can innovators, funders, and governments align incentives so that every dollar of external capital also builds domestic capability?</p><p>The promise is real. The peril is real too.</p><p>As I write, choices are being made in negotiation rooms, procurement offices, and boardrooms. The America First Global Health Strategy may be designed to advance American interests, but it will only succeed where African systems accept or enable that design. The smarter strategy for Africa is not to reject American engagement wholesale but to insist that engagement builds African capacity, preserve data sovereignty, and support local industrialization.</p><p>Because the ultimate truth is simple: no global health vision, American, Chinese, or European, will succeed without African design, African data stewardship, and African entrepreneurship at its core.</p><p>The choice is ours. Will Africa remain the testbed of others’ ambitions, or will it become the blueprint of its own future?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*9J78YFiO3nlCL3fGHmbKlw.jpeg" /><figcaption><strong>Collaborating with other Biotech Leaders of tomorrow at GapSummit in Cambridge.</strong></figcaption></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5f5793734d6b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/included-vc/how-the-america-first-global-health-strategy-shapes-africas-health-technology-ecosystem-5f5793734d6b">How the America First Global Health Strategy Shapes Africa’s Health Technology Ecosystem</a> was originally published in <a href="https://medium.com/included-vc">Included VC</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Could Nigeria’s HealthTech Be in Its Fintech 2015–2017 Era?]]></title>
            <link>https://medium.com/included-vc/could-nigerias-healthtech-be-in-its-fintech-2015-2017-era-97d220597a00?source=rss-48914a38ef9a------2</link>
            <guid isPermaLink="false">https://medium.com/p/97d220597a00</guid>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Isaac Ekundayo, MD]]></dc:creator>
            <pubDate>Thu, 18 Dec 2025 09:02:30 GMT</pubDate>
            <atom:updated>2025-12-24T14:10:07.803Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bmd9SKyGk02A-FZIHoF0zg.png" /><figcaption>Nigeria’s Health Tech Vs Fintech: Lessons Learnt</figcaption></figure><p>As a <a href="https://www.linkedin.com/in/isaac-ekundayo/">Nigerian medical doctor</a>, I have navigated the country’s health ecosystem from multiple vantage points: working with one of the world’s largest global health implementation partners (<a href="https://www.clintonhealthaccess.org/">Clinton Health Access Initiative</a>), consulting for healthtech startups at a <a href="https://techcabal.com/2023/04/20/inc-consulting-africa-launches-with-a-drive-to-improve-innovation-in-africas-healthcare-sector/">boutique firm</a> in Lagos, Nigeria, contributing to Novartis-funded malaria research, piloting digital health spinouts, and most recently founding <a href="https://x.com/medintechafrica">Medintech Africa</a>, an incubator that supports student-led healthtech innovations and places residents in live public-private partnership pilots.</p><p>These experiences have given me a front-row seat to the bottlenecks Nigerian healthtech founders contend with:</p><ol><li>Fragmented payer systems</li><li>Uncertain exit pathways</li><li>And regulatory ambiguity.</li></ol><p>Strikingly, these <a href="https://assets.kpmg.com/content/dam/kpmg/ng/pdf/ng-fintech-in-nigeria-understanding-the-value-proposition.pdf">hurdles echo those faced by fintech startups between 2015 and 2017</a>, when the sector attracted record funding yet remained stifled by regulatory bottlenecks, fragile infrastructure, partnership barriers, and widespread trust deficits. Despite fintech commanding <a href="https://techcabal.com/2018/08/03/the-challenges-nigerian-fintech-startups-want-out-of-their-way/">45% of Africa’s total startup funding in 2017 </a>and companies like Flutterwave raising landmark rounds, growth was constrained by antiquated regulations, difficulty accessing scale capital, and customer skepticism.</p><p>Over time, fintech’s path forward required not only technology but also strategic partnerships with banks, proactive regulatory engagement, and the importation of mid-level talent from traditional finance to bridge execution gaps.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/608/1*Xtw24uF6kKeJJCinrHnlpQ.gif" /></figure><p>Healthtech today stands in a similar moment of high promise but systemic friction. The sector is drawing unprecedented interest from investors and policymakers, yet founders are still forced to navigate unclear licensing regimes, infrastructural fragility, and patient trust issues that mirror fintech’s earlier battles. The key difference is that while fintech could lean on established banks to scale, healthtech must build collaborative bridges with hospitals, insurers, regulators, and government agencies — actors often even slower-moving than financial institutions.</p><p>This deep dive draws on those lived lessons and supplements them with structured insights from a survey of health technology founders, investors, and policymakers across Nigeria. The result is a ground-level perspective on what’s working, what isn’t, and where the ecosystem is truly headed, arguing that just as fintech overcame its bottlenecks through partnership, policy adaptation, and credibility-building, healthtech can tow a similar path.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/720/1*PwT65jIfaqmrwGg1mJPjQg.jpeg" /><figcaption>Nigeria’s Health tech taking notes from the Fintech ecosystem</figcaption></figure><h3>A. Funding Trajectories &amp; Capital Stack</h3><p>Nigeria’s fintech journey between 2015 and 2017 offers the clearest historical analogue for where healthtech might head. In that period, fintechs moved from fragmented early-stage struggles to breakout growth, buoyed by inflows of foreign capital and increased policy clarity.</p><p><a href="https://www.pwc.com/ng/en/assets/pdf/fintech-banking-sector-nigeria.pdf">By 2018, fintechs captured 58% of Nigerian startup funding, about $103 million out of $178 million,</a> a sharp signal that investor confidence had shifted decisively toward the sector. Fintech’s “gold rush moment” arrived when fragmented startups suddenly found themselves at the center of investor attention, catalyzed by regulatory sandboxes and bank partnerships.</p><p>But the comparison only holds up to a point. <strong>Two key divergences matter.</strong></p><p>First, the composition of early capital. Fintechs in their formative years were constrained by a shallow domestic VC base and leaned heavily on foreign inflows; over 70% of their early capital came from abroad. Healthtech is repeating that pattern, but with an even stronger dependence on catalytic grants and DFI-linked programs.</p><p>As highlighted in Digital Health Nigeria’s <a href="https://medium.com/digital-health-nigeria/2019-in-nigerian-health-tech-and-trends-to-watch-for-in-2020-9df933447d21"><em>2019 Trends to Watch</em></a> piece, healthtech founders often struggled to raise equity unless they first stacked “non-dilutive grant capital” to de-risk their ventures. From my work at <a href="https://techcabal.com/2023/04/20/inc-consulting-africa-launches-with-a-drive-to-improve-innovation-in-africas-healthcare-sector/">INC Consulting</a>, I repeatedly saw healthtech founders unable to unlock even pre-seed rounds without grant scaffolding or friends-and-family capital. Our survey confirmed this: very few Nigeria-based funds are actively investing in healthtech, and where they exist, they remain cautious, requiring proof points from grants or pilots before committing equity. In short, just as fintech’s early rocket fuel came from offshore capital, healthtech today depends on grants to bridge the absence of deep local risk capital.</p><p>Second, regulatory drag in healthtech is even worse. In 2017, while fintech was starting to benefit from clearer licensing frameworks, healthtech was in a rut: state-level differences in approvals, ethical review boards, and payer gatekeepers.</p><p><a href="https://www.pwc.com/ng/en/assets/pdf/fintech-banking-sector-nigeria.pdf">A PwC fintech report</a> documented how startups faced an “unclear regulatory environment” — uncertain licensing rules, multi-year approval delays, and the ever-present threat of stifling overregulation. Healthtech inherited all of that friction, compounded by the complexity of health sector oversight. Diagnostics validation, digital health licensing, payer integration, and state-by-state variations in approvals can stretch timelines even longer than fintech faced. Where fintech startups could, at least in theory, piggyback on banks and established rails, healthtech must navigate a maze of health agencies, insurers, and hospital systems; each with its own points of friction.</p><p>The result is a capital stack bottleneck. A handful of players, <a href="https://heliumhealth.com/">Helium Health</a>, <a href="https://getreliancehealth.com/nigeria/">Reliance</a>, <a href="https://remedial.health/about-us">Remedial</a>, <a href="https://www.mdaas.io/">MDaaS</a>, are breaking into early growth, but the majority remain stuck at the pre-seed stage, dependent on angels, micro-VCs, and SAFEs/convertible notes. As the <a href="https://digitalhealthnigeria.substack.com/p/a-year-in-nigerian-health-tech-2020">Digital Health Nigeria <em>2020 Review</em> noted</a>, while fintech was producing “mega-deals,” healthtech was still dominated by “small grant-funded experiments” with limited visibility into exits. Just as retail investor distrust clouded fintech’s early exit pathways, today’s fragmented payer environment obscures exit visibility in healthtech, leaving founders and investors alike without clear horizons.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/595/1*aXqfqldNnsLPcssqoiAteA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/595/1*LQRI9IQ9llgby2jpLqBH7w.png" /><figcaption>PS: This is not an exhaustive list. Please reach out via <a href="https://www.linkedin.com/in/isaac-ekundayo/">LinkedIn</a> if your fund wasn’t highlighted</figcaption></figure><p>Yet, there are signs that Healthtech 1.0, the experimental, grant-heavy phase, is beginning to give way to Healthtech 2.0. In 2018, healthtech was still about “isolated pilots”; by 2019, we began to see a shift toward “platform plays” like Helium digitizing providers; and by 2020, the argument was clear that “infrastructure-first companies” were laying the rails. In the same way fintech’s growth after 2018 was fueled not just by capital but by rails built in earlier years (Interswitch, NIBSS, and bank adoption of digital infrastructure), healthtech is now laying (and layering) its own foundations. Companies like <a href="https://heliumhealth.com/">Helium Health</a>, <a href="https://mpharma.com/">mPharma</a>, and <a href="https://www.wellahealth.com/">Wellahealth</a> are digitizing providers, standardizing health records, and creating the “rails” for data and financing flows. This is hard, expensive, infrastructure-first work, but it is the necessary precondition for the consumer-facing, scale-driven innovations that will follow. Just as fintech 2.0 consumerized payments with sleek user interfaces and mass adoption, healthtech 2.0 will consumerize care with integrated payer platforms, patient-facing tools, and scalable PPP-backed infrastructure.</p><p>Our survey reinforced one possible unlock: blended finance as the real enabler. Operators consistently pointed to public-private partnerships (PPPs), especially in diagnostics, logistics, and primary care rollouts, as the most natural structures for absorbing risk and scaling reach. Investors, for their part, expressed growing openness to results-based financing (RBF) in pharmacy and diagnostics, provided repeatability and cost-recovery patterns could be demonstrated. An anonymous founder of a discontinued health tech startup underscored this point, warning that unless blended capital models emerge, health tech will remain in “perpetual pilot mode.” Over half of operators ranked PPP as their strongest growth lever; investors leaned toward RBF as soon as evidence pipelines became predictable.</p><p>Here again, fintech leads the way. Its breakout was not powered by equity alone but by hybrid structures; international VC layered on bank partnerships and regulatory sandboxes. Agency banking, mobile money, and shared payment rails acted as blended finance vehicles, de-risking the sector long enough for equity capital to scale. In practice, bank partnerships became the PPPs of fintech’s era.</p><p>For healthtech, the implication is clear: equity alone cannot carry the weight. Blended stacks, first-loss catalytic capital, RBF pilots, and PPP models must be deliberately wired into the sector’s capital architecture. Equity should be conserved for building software moats and regional expansion, while blended structures absorb the early risk of infrastructure-heavy interventions.</p><p>The policy beat is equally clear. Just as NIBSS, NIN etc catalyzed fintech’s ascent, structured PPP pilots with embedded blended finance could become the unlock for healthtech’s next wave. The transition from Healthtech 1.0 to 2.0 is already underway , the question now is whether policymakers and investors will accelerate it or whether founders will remain trapped in perpetual pilot mode.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*fEO2G3XmGghFGMfgsyHsIg.jpeg" /><figcaption>So much work to be done. Argghhh!</figcaption></figure><h3>B. Business Model &amp; Unit Economics</h3><p>In HealthTech 1.0, most Nigerian startups leaned on direct-to-consumer (B2C) models, apps for doctor consultations, pharmacy delivery services, and telemedicine platforms that assumed users would directly pay out-of-pocket. While these services addressed real gaps in access, their business models were fragile. Customer acquisition costs were unsustainably high in a fragmented, low-trust market, while lifetime value was low in a country where 75% of health spending is still out-of-pocket. As one founder of a discontinued telemedicine startup put it in our survey, <em>“We spent more on marketing to acquire each patient than the margin we ever made back.”</em> Margins evaporated as startups were forced to subsidize services to build early adoption.</p><p>Some companies experimented with B2B contracts, selling to HMOs, hospitals, and corporates. But here, too, the economics faltered. Long sales cycles, opaque procurement processes, and delayed payments stretched working capital thin. One survey respondent who asked to be anonymous noted, <em>“We closed contracts worth millions, but cash flow was a nightmare; payments took six to nine months.”</em> This meant revenue growth often failed to translate into profitability. Much like <a href="https://assets.kpmg.com/content/dam/kpmg/ng/pdf/ng-fintech-in-nigeria-understanding-the-value-proposition.pdf">fintech circa 2015</a>, healthtech firms were chasing user numbers without cracking the sustainability of their unit economics.</p><p>The contours of HealthTech 2.0 are emerging. Instead of replicating Silicon Valley’s direct-pay models, Nigerian founders are aligning business models to where the health system’s money actually flows, and investors are beginning to converge on the same insight.</p><ul><li><strong>Health Financing &amp; Insurance</strong>: The single most cited high-ROI segment by investors. Embedding care into micro-premiums or subscription packages (often in partnership with fintechs) creates recurring revenue streams, reduces churn, and tackles the out-of-pocket payment problem head-on.</li><li><strong>Pharmacy Supply Chains</strong>: Another clear ROI winner. Investors repeatedly highlight supply chains as a backbone play. <a href="https://www.pharmacymarts.com/">Pharmacy Mart</a>, as highlighted by an investor, for instance, demonstrates how digitizing procurement and distribution can generate volume-driven margins and reduce leakages in a <a href="https://www.pharma-westafrica.com/market-overview">$4B+ Nigerian medicines market.</a></li><li><strong>SaaS Platforms for Clinics, Pharmacies &amp; Labs</strong>: Platforms that manage patients, payments, and logistics generate sticky, annuity-like revenues with higher margins, as switching costs are significant once embedded.</li><li><strong>Diagnostics at Scale</strong>: Lower-ticket, higher-frequency services like point-of-care testing can be monetized sustainably, especially when tied into last-mile supply chains.</li><li><strong>Public-Private Alignment</strong>: Donor agencies and state governments collectively control a major share of healthcare spending. As one founder put it, <em>“Our biggest break came when we stopped chasing individual patients and started providing digital logistics for a state immunization program.”</em></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dV3mMZICaKN25jPE-tQc8g.png" /><figcaption>PS: This is not an exhaustive list. Please reach out via <a href="https://www.linkedin.com/in/isaac-ekundayo/">LinkedIn</a> if your startup wasn’t highlighted.</figcaption></figure><p><strong>The Role of Localization</strong></p><p>Investors are divided: some stress that localization (USSD, offline-first design, local languages) is essential for adoption, while others caution that it’s not sufficient as a moat unless paired with a strong business model.</p><ul><li><strong>Investor Example</strong>: <a href="https://tanzmed.africa/">Tanzmed</a> (Tanzania) — An “everything app” that bundles multiple small-margin services into one stronger-margin platform. Its localization is twofold: the user experience (accessible, language-aware) and the business model (bundled, sticky, ecosystem-driven).</li><li><strong>Investor Example</strong>: <a href="https://tibu.africa/">Tibu Health</a> (Kenya) — Built with USSD/offline-first capabilities, directly addressing local context. Adoption hinged not just on the product but also on policy support around digital health infrastructure.</li></ul><p><strong>The lesson:</strong> localization matters most when it amplifies unit economics, not when pursued in isolation.</p><p><strong>In this shift, unit economics begin to resemble fintech post-2018:</strong> lower acquisition costs via ecosystem partnerships, predictable revenue through more hybrid models, and clearer exit pathways through integration with insurers, banks, or even global health players.</p><p>HealthTech 2.0, then, is less about shiny apps and more about infrastructure and business models that prioritize predictable revenue streams, lower acquisition costs, and scalable margins. Just as fintech’s leap forward was catalyzed by payments infrastructure (think Paystack, Flutterwave), healthtech’s next leap will be built on interoperable systems that make healthcare transactions smoother, faster, and ultimately profitable.</p><h3>C. Regulation: What Fintech Fixed — and What Healthtech Must</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lXfERsLC1MujspZeN8aW-w.jpeg" /></figure><p>One of the most decisive enablers of Nigeria’s fintech boom was the eventual shift in regulation from ambiguity to structured support. In its early years, fintech suffered under what a <a href="https://www.pwc.com/ng/en/assets/pdf/fintech-banking-sector-nigeria.pdf">report by PwC</a> described as an “unclear regulatory environment”: multiple regulators, overlapping mandates, and slow approvals that made innovation risky. But over time, regulators adjusted. The Central Bank of Nigeria launched USSD frameworks combined with BVN and later NIN integration, providing clarity, legitimacy, and distribution rails that gave investors confidence. In short, fintech scaled not only because of capital inflows but also because regulators created enabling structures that reduced uncertainty.</p><p>Healthtech today sits where fintech was before 2017, but the regulatory fog is even thicker. Instead of a single anchor regulator like the CBN, healthtech founders must navigate a maze of agencies: the Federal Ministry of Health, NHIA, NAFDAC, MDCN, MLSCN, NPHCDA, and state-level ministries, all without a harmonized “one-stop shop.” The result is fragmented approvals, unclear licensing sequences, and policy contradictions. <a href="https://www.linkedin.com/in/irene-nwaukwa?originalSubdomain=ng">Irene Nwakwua</a> of <a href="https://www.infinityhealth.africa/">Infinity Health</a> in our survey put it bluntly: <em>“It hasn’t affected my business model”</em> when asked how the NHIA Act shaped their work, <a href="https://www.linkedin.com/in/ikpemeneto/?originalSubdomain=ng">Dr. Neto Ikpeme</a> of <a href="https://www.wellahealth.com/">WellaHealth</a> also noted that the Act had forced them to seek a license <em>“that is yet unavailable.”</em> These comments reveal what fintech also faced in its early years: laws exist on paper, but the enabling structures to implement them are missing.</p><p>The absence of a digital health sandbox compounds the drag. Fintech entrepreneurs can test products in CBN’s sandbox; healthtech founders have no supervised lane for telemedicine, e-pharmacy, AI diagnostics, or claims APIs. Instead, they run unsupervised pilots, carrying compliance risk alone. Policy implementation partners confirmed this in our survey: one noted that reimbursement pathways were unclear, while another said, “Telemedicine<em> will require another 3–5 years before regulations are ready.”</em> Without sandboxes, regulatory timelines stretch into years, and innovation stalls in perpetual pilot mode.</p><p>Data governance is another gap. Fintech benefited from national identity rails (BVN, NIN) and API-level security requirements that enabled interoperability and secure data sharing. Healthtech lacks both. Startups face a vacuum on patient identity matching, consent management, and interoperability standards. One survey respondent called for a <em>“national interoperability standard supported by reliable internet,”</em> while another stressed the need for <em>“public-private partnerships for digital integration”</em> and <em>“open health data sharing.”</em> The message is clear: without standardized data rails, healthtech cannot scale beyond silos, and investors cannot underwrite results-based financing or blended finance models with confidence.</p><p>Insurance integration is another critical missing piece. Several founders highlighted that current insurance adoption is too low to support viable digital models. One suggested that making health insurance compulsory, <em>“like third-party car insurance,”</em> would radically change the economics of the sector. Another pointed out that insurers do not cover key demographics like the elderly, forcing startups into costly workarounds. This echoes fintech’s early struggles with low retail investor trust; without credible payers in the system, exit pathways remain thin.</p><p>Regional comparisons reinforce Nigeria’s lag. Multiple respondents pointed to Kenya and South Africa as leaders in digital health scalability. Kenya was praised for <em>“embracing digital-first solutions in finance and extending them into health,”</em> while South Africa was cited for <em>“a well-defined national digital health strategy and large-scale adoption of hospital IT systems.”</em> Nigeria, by contrast, was rated poorly: one operator scored the regulatory environment just 2 out of 5 for readiness, another admitted <em>“no policy comes to mind at the moment,”</em> and others described their integration with NHIA as an “uphill battle.”</p><p>The lesson from fintech is clear: regulation does not have to stifle innovation. Fintech’s breakthrough came only when regulators harmonized roles, created test environments, issued licenses tailored to business models, and secured data rails. For healthtech, the same choreography is urgently needed: an active Health Innovation Steering Committee to coordinate across regulators; a national digital health sandbox for supervised testing; fit-for-purpose digital health licenses for telemedicine, diagnostics, and pharmacy; and codified interoperability standards tied to the national ID system. Without these reforms, healthtech will remain grant-dependent and stuck in pilot mode, unable to replicate fintech’s growth curve.</p><p>In short, fintech shows how regulatory clarity can unlock investor confidence and accelerate scale. Healthtech needs the same decisive moves, harmonized oversight, sandboxes, insurance integration, and data rails if it is to move from Healthtech 1.0’s experimentation into Healthtech 2.0’s scale. Until then, Nigerian founders will continue to face an uphill regulatory battle while peers in Kenya and South Africa race ahead.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/595/1*D5bTZFrpPU3uMSJjOHjo8A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/595/1*aAzmWA-FeWCpHpEuzgYezg.png" /></figure><h3>D. Go-to-Market: Cracking Distribution</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/739/1*6ydgXX-IvgDgKIY8ujwW5Q.jpeg" /></figure><p>If fintech taught Nigeria’s startup ecosystem one lesson, it’s that scale is not achieved by sleek apps alone but by solving distribution and trust. In its early years, fintechs struggled to win consumers one by one; acquisition costs were high and skepticism was widespread. The breakthrough came when fintechs aligned with existing rails: banks provided legitimacy and ready customer bases, telcos opened USSD channels to reach the mass market, and agent networks delivered last-mile coverage. The <a href="https://sec.gov.ng/wp-content/uploads/2020/09/Report-of-the-FinTech-Roadmap-Committee-of-the-Nigerian-Capital-Market_-October-14-2019.pdf"><em>Fintech Roadmap Committee Report</em></a> highlighted that these partnerships, not just venture capital, were what unlocked adoption at scale.</p><p>Healthtech today is replaying fintech’s pre-2017 struggles. Many HealthTech 1.0 startups launched as direct-to-consumer apps; telemedicine, pharmacy delivery, or digital consultation platforms. While these solved access problems, the economics were brittle: high customer acquisition costs, low willingness to pay in an out-of-pocket market, and fragile trust. As one survey respondent noted bluntly, <em>“Traditional hospitals see healthtech as competition rather than complementary services.”</em></p><p>But HealthTech 2.0 is starting to crack the GTM code by learning from fintech’s partnerships-first strategy. Our survey confirmed three major shifts:</p><ol><li>Build on existing behaviors. Just as fintech layered mobile wallets on cash habits, healthtech must align with how Nigerians already access care, through pharmacies, informal providers, and community health workers. One operator put it clearly: <em>“Community health agents, pharmacy networks, and mobile health units are the real distribution game-changers.”</em></li><li>Infrastructure first, consumerization next. Fintech only scaled after payment rails (BVN, NIBSS, agency banking) were in place. Healthtech founders echoed this: <em>“Healthtech needs digital backbones like EMRs, inventory systems, and payment layers.”</em> Platforms like Helium Health and Remedial are laying these rails; consumer-facing apps can only compound once they exist.</li><li>Trust and simplicity are the unlock. Just as fintech apps prioritized reliability, easy design, and transparency, healthtech must do the same. Survey respondents stressed <em>“simplicity and trust; building easy-to-use solutions that solve real problems while earning user confidence.”</em> Without this, healthtech adoption stalls no matter the product.</li><li>Monetize indirectly. Fintech rarely charged end-users directly; instead, they monetized through merchants, banks, and transaction fees. Healthtech must follow suit, leaning on insurers, employers, pharmacies, and PPP contracts to underwrite adoption rather than expecting fragile households to pay.</li><li>Localization is non-negotiable. Perhaps the strongest survey finding is how critical offline-first and language-based models have been to healthtech adoption. Respondents repeatedly ranked localization as a “4” or “5” in importance, with “offline-first” cited as the most effective feature for growth. The challenges are clear: <em>low digital literacy, weak infrastructure (power/internet), and the high cost of building multi-channel products (USSD + app + web).</em> Yet these barriers mirror fintech’s early struggles, when USSD and agent networks broke through to mass adoption. As one founder put it, <em>“offline-first is what makes people trust and use the product — apps alone won’t work here.”</em></li></ol><p>Taken together, the contours of a viable GTM strategy are visible. Healthtech startups are embedding into provider workflows (B2B SaaS for hospitals, pharmacies, and labs), hitching onto PPP rollouts in diagnostics and logistics, and experimenting with insurance-linked bundles to create steady, predictable revenue streams. But critically, they must also invest in localization; offline-first, USSD, and multilingual interfaces, just as fintech did with agency banking and USSD wallets.</p><p><strong>The lesson is simple but decisive:</strong> going to market in Nigeria is not about outspending on consumer marketing; it’s about embedding into existing trust and distribution systems. For fintech, those were banks, telcos, and agents. For healthtech, they will be hospitals, pharmacies, insurers, community health agents, and localized, offline-first products. And just as fintech discovered, once the rails are laid and localized channels open, adoption compounds at breathtaking speed.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/595/1*xuRT_IG89do3RtFfz72dYQ.png" /><figcaption><strong>The question now is, who is the Interswitch of Nigeria’s health technology?</strong></figcaption></figure><h3>E. Case Studies (Scale Drivers &amp; Pitfalls)</h3><h4>1. WellaHealth Technologies</h4><p><a href="https://www.wellahealth.com/">WellaHealth Technologies</a>, founded in 2018 by <a href="https://www.linkedin.com/in/ikpemeneto?originalSubdomain=ng">Dr. Ikpeme Neto</a>, has become one of Nigeria’s most compelling examples of what a HealthTech 2.0 company looks like in practice. Rather than attempting to disrupt existing structures with glossy apps or AI-heavy solutions, WellaHealth has concentrated on building the infrastructure that makes healthcare digitization possible at scale. Its focus has been clear: empower community pharmacies, integrate with insurers, and create distribution rails that enable affordable, sustainable access to care. This approach has paid off. In 2024, the company announced it had processed ₦1.4 billion in pharmacy benefits through its digital platform, reaching over 2,000 pharmacies across all 36 Nigerian states and serving more than 300,000 patient visits with an 81% partner satisfaction rate.</p><p>The company’s business model is rooted in B2B SaaS, which has proven the most profitable path for healthtech in Nigeria. By offering pharmacies, hospitals, and corporates tools for prescription verification, claims management, and payments, WellaHealth earns steady subscription revenues while reducing the inefficiencies that have long plagued the sector. Insurers integrate with the platform to distribute affordable micro-health plans, while corporates and governments tap into its infrastructure through public-private partnerships. This model addresses the three biggest weaknesses of early HealthTech 1.0 startups — high customer acquisition costs, low lifetime value, and fragile margins — by building growth on top of existing healthcare and financing systems. As Neto puts it, growth has been the result of persistence and compounding: it took ten quarters to process the company’s first billion, but only four to hit the next and just two to cross the third.</p><p>WellaHealth’s go-to-market strategy draws heavily from fintech’s playbook. Offline-first design, SMS and USSD integration, and multilingual communication have made the platform usable in low-bandwidth, low-literacy contexts. This localization has been critical for adoption, as survey findings confirm that Nigerian users place high value on trust, convenience, and accessibility over advanced features. Partnerships have been another defining pillar. By embedding into pharmacy networks, insurers, and even telcos, WellaHealth has been able to scale distribution and profitability far faster than pure B2C models could achieve. In many ways, pharmacies have become WellaHealth’s equivalent of fintech’s agent networks — the trusted, local infrastructure that makes digital adoption possible.</p><p>The impact of this approach is visible across Nigeria’s healthcare system. Pharmacies that once served only as points for dispensing drugs are now functioning as comprehensive primary care hubs, enabled by digital tools. Patient access to medicines and basic care has improved significantly, especially in underserved regions, while pharmacies themselves are reporting increased footfall and revenues. One partner in Lagos noted that daily patient referrals from WellaHealth had materially grown their business and that the Wellapartner app had simplified everything from patient care to payments. By focusing on digitization and enablement rather than disruption, WellaHealth has modernized inventory management, created more reliable patient record systems, and built the rails for insurers and governments to scale health coverage more effectively.</p><p>The lessons from WellaHealth’s journey are instructive for the broader ecosystem. First, Africa’s toughest health challenges cannot be solved by AI or shiny tech features alone but require grit, persistence, and infrastructure-first thinking. Second, compounding growth is the real unlock; what looks like slow progress in the early years can accelerate sharply once distribution networks are in place. Third, profitability in healthtech comes not from direct-to-consumer apps but from partnerships with pharmacies, insurers, and telcos that already hold the trust of end-users. And finally, localization, offline-first design, multilingual support, and low-cost distribution channels are not optional but fundamental in an environment defined by infrastructure deficits and low digital literacy.</p><p>WellaHealth’s success shows what is possible when healthtech aligns with the realities of Nigeria’s healthcare landscape rather than importing Western models wholesale. By prioritizing infrastructure, partnerships, and localization, the company has created one of Africa’s largest digital pharmacy networks and a sustainable business that continues to expand into new services and geographies. It is a case study in how HealthTech 2.0 can scale: not by building shiny apps, but by building the rails on which the rest of the ecosystem can grow.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/854/1*TJqKtf_nutNu2zlKiawyTA.png" /><figcaption>Source: <a href="https://www.thisdaylive.com/2024/05/08/wellahealth-partners-with-mtn-to-make-health-insurance-accessible-affordable-for-nigerians/">thisdaylive</a></figcaption></figure><h4>2. EMedrep and Pronov — Lessons from Discontinued Startups</h4><p><a href="https://tracxn.com/d/companies/emedrep/__7PSMO5XLxG_c7hhNDkvy0WKB4cfWdvppBJqUNU8QdGw">EMedrep</a> began as a bold attempt to digitize how pharmacies restock and access credit in Nigeria. Founded with the vision of becoming a “go-to” platform for community pharmacies the startup quickly identified a critical pain point: community pharmacies often struggled with fragmented supply chains, limited logistics support, and the absence of credit systems to smooth out restocking cycles. The market was receptive, pharmacies in Lagos and Ogun embraced the idea, and early iterations revealed strong demand for a platform that combined credit access with reliable logistics. Over time, Medrep built a loyal customer base and appeared poised to scale.</p><p>Yet the company’s trajectory illustrates how fragile early-stage healthtech ventures can be when capital structures are misaligned. Medrep’s seed deal involved ₦10 million offered “to be released upon request,” contingent on the approval of four directors. In practice, this created bottlenecks, as the founder had to negotiate each cash request. While the investors contributed more than capital, building the platform and providing office space valued at roughly ₦40 million, the terms left little flexibility for agile decision-making. Compounding this was the equity trade-off: 35% of the company in exchange for an investment structure that effectively locked the founder out of strategic control. Eventually, unable to hit growth goals under these constraints, the founder sold the company.</p><p>The journey did not end there. The same founder later took on a role at <a href="https://x.com/PronovHealth">ProNOV</a>, a Bill and Melinda Gates Foundation–backed digital financial inclusion project targeting pharmacies. ProNOV’s model addressed another systemic challenge: the dominance of cash in healthcare transactions. By creating a lean, mobile-based business intelligence tool, the platform enabled retail pharmacists to accept digital payments securely, affordably, and conveniently. The goal was to increase merchant acceptance of digital transactions, reduce reliance on cash, and ultimately encourage low-income households to adopt digital payment mechanisms for healthcare spending. It was a hybrid fintech-healthtech play, showing how financial inclusion could serve as a lever for healthcare access.</p><p>Despite these promising foundations, ProNOV ran into the same barrier faced by many healthtech startups in Nigeria — funding. After redefining the product’s core proposition and cutting operational costs by 96%, the company even achieved profitability for the first time. Yet without access to fresh capital, growth stalled, and the platform eventually shut down. Investors recognized the potential, with some urging the founder to launch another pharmatech venture, but exhaustion and the weight of previous experiences made restarting untenable.</p><p>The combined story of Medrep and ProNOV offers several lessons for the Nigerian healthtech ecosystem. First, capital structure matters as much as capital itself, restrictive deal terms can cripple agility at precisely the stage when startups need to experiment and iterate. Second, infrastructure challenges in healthcare supply chains and payments remain a significant opportunity, as both ventures demonstrated strong product-market fit before financial realities cut them short. Third, profitability alone does not guarantee sustainability in healthtech: without investor confidence and aligned funding models, even lean and effective companies can falter.</p><p>In hindsight, Medrep and ProNOV were ahead of their time. Today, as HealthTech 2.0 gains momentum with a stronger emphasis on infrastructure, interoperability, and blended financing, their experiences stand as both a warning and a roadmap. The demand for pharmacy credit systems, logistics enablement, and digital payment rails has not gone away — in fact, it is more urgent than ever. What was missing was the capital scaffolding and policy support to give these ideas room to grow.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/480/1*w8paSF3WfdaeQee0U4cFPA.gif" /></figure><h4><strong>3. Discontinued Anonymous Telemedicine Startup</strong></h4><p>In 2018, a Nigerian founder set out to solve one of the country’s most pressing challenges: access to care. The vision was simple yet ambitious: use telemedicine to bridge the gap between patients and qualified doctors, particularly in underserved communities where healthcare access was limited. The startup launched with optimism, building a platform to connect patients with clinicians via smartphones and the internet, offering a promise of affordable and convenient consultations.</p><p>The market signals were encouraging. Surveys had shown that Nigerians were open to telemedicine if it improved convenience and reduced waiting times. For a moment, it seemed as though the pieces were aligned: rising mobile penetration, growing interest in digital health, and the success stories of fintechs suggested that healthcare could be the next frontier.</p><p>But the realities of building a telemedicine company in Nigeria soon proved unforgiving. The startup was entirely bootstrapped, with only modest support from a small local program. Venture capital interest was minimal, and donor funding was unavailable. This created severe funding constraints, limiting the company’s ability to scale, market aggressively, or subsidize services long enough to build patient trust. The founder later reflected, “The<em> market was there, but there were challenges around payment and financing.”</em></p><p>Payment and financing were indeed critical barriers. Unlike fintech, where digital wallets and bank transfers were already ingrained in user behavior, healthcare required new spending habits. Patients — most of whom paid out-of-pocket — hesitated to pay for digital consultations upfront. Integration with health financing schemes like insurance was absent, leaving the platform vulnerable to the harsh economics of direct-to-consumer healthtech.</p><p>Technical and infrastructure challenges compounded the situation. Internet connectivity remained patchy in rural areas where the need for telemedicine was greatest. Smartphone penetration, while improving, was still low among the target population. The result was a service designed for the very people least able to reliably access it.</p><p>After 2–4 years of struggle, the startup shut down. The founder, reflecting on the journey, was candid about the lessons learned:</p><ul><li>On the model: “If I could go back, I would not launch a telemedicine company.</li><li>On integration: “Better health financing integrations are essential — without them, patients simply won’t pay.”</li><li>On timing and strategy: “Understand the market and behaviors before building anything.”</li></ul><p>This experience highlights a broader truth about HealthTech 1.0 in Nigeria. While telemedicine appears attractive on paper, without the infrastructure rails — affordable internet, financing pathways, and strong trust networks — it is difficult to sustain. Unlike fintech, which rode on pre-existing rails like NIBSS and agent networks, healthtech entrepreneurs often have to build both the product and the enabling infrastructure at the same time.</p><p>The anonymous founder’s story underscores the cautionary tale that not all healthcare innovations fail because of lack of demand; sometimes, they collapse because the ecosystem needed to sustain them is not yet in place. As HealthTech 2.0 emerges, with a stronger emphasis on insurance integration, offline-first design, and blended financing models, the lessons from this failed telemedicine startup remain invaluable.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*THNm7KK-akGqB38Q5-13CA.jpeg" /><figcaption><strong>&quot;Efile E je ko start&quot; is translated as &quot;leave him; let him start.&quot;</strong></figcaption></figure><h3>E. Benchmarking Nigeria, Kenya, South Africa</h3><p>When operators and investors were asked which African countries are furthest along in digital-health scalability, three names emerged most often: South Africa, Kenya, and Nigeria. Each country leads on different dimensions, and the pattern matters because scalability is not a single binary; it’s the intersection of policy readiness, infrastructure, payer depth, private-sector capacity, and user adoption. Below I compare the three across those dimensions and draw practical lessons for Nigeria.</p><p><strong>Policy &amp; regulatory readiness.</strong> Respondents repeatedly pointed to South Africa as having the clearest policy environment: a national digital-health strategy, stronger government support, and more visible large-scale rollouts. Several operators measure readiness by the presence of governance/policy instruments and say South Africa “has used digital tools in hospitals and clinics on a large scale.” Kenya also scores highly for policy openness — many respondents highlighted Kenya’s willingness to adopt standards (e.g., FHIR-style approaches) and to integrate digital tools into public systems. Nigeria scores lowest on this axis in operator perception: multiple founders described NHIA integration as an “uphill battle,” and several respondents rated Nigeria’s regulatory readiness poorly. <strong>In short: South Africa = policy scale; Kenya = policy agility; Nigeria = policy fragmentation.</strong></p><p><strong>Infrastructure &amp; digital backbone.</strong> South Africa benefits from relatively advanced ICT infrastructure (higher broadband/4G/5G penetration in key urban corridors) and more mature hospital IT deployments, conditions that make nationwide pilots and IoMT rollouts easier. Kenya’s digital public goods (identity, mobile money ubiquity) and pragmatic government programs give it a structural advantage despite more modest infrastructure than South Africa. Nigeria’s infrastructure is heterogeneous: dense digital services in cities but serious gaps in last-mile connectivity and power. Surveyed operators stressed that offline-first UX, USSD, and multilingual interfaces are necessary in Nigeria, signaling that infrastructure still constrains universal digital service delivery.</p><p><strong>Payer depth and reimbursement pathways.</strong> A recurring reason respondents ranked South Africa and Kenya ahead is payer maturity. One respondent cited ~15% insurance coverage in South Africa (their working measure) and noted that this payer base supported telemedicine and IoMT scaling during COVID. Kenya is credited with concrete payer integrations (even early telemedicine coverage). In Nigeria, low formal insurance penetration and fragmented NHIA implementation hurt unit economics: many startups must rely on grants, donor funding, or awkward workarounds to monetize. Operators explicitly requested “better health financing integrations” as the single biggest accelerator for Nigeria. <a href="https://www.linkedin.com/in/irene-nwaukwa/?originalSubdomain=ng">Irene Nwakwa</a>, CEO, <a href="https://www.infinityhealth.africa/">Infinity Health</a> further highlighted, “<em>the challenge with scaling digital health in Nigeria is that insurers remain relatively insular, with limited client bases that can’t yet absorb the cost of most solutions. This is compounded by Africa’s fragmented regulatory systems, requiring tailored strategies per region, alongside the urgent need for seamless payment systems and the inherent risk of credit.”</em></p><p><strong>Private-sector ecosystem &amp; talent.</strong> Nigeria leads in sheer startup volume and “outward expansion” (more Nigerian startups scaling into other African markets), which respondents acknowledged. Yet several noted that South Africa’s and Kenya’s private ecosystems produce more repeatable national rollouts — partly because of closer public-private coordination and partly because investors and incumbents there more readily underwrite pilots that scale. Nigeria’s talent pool is strong technically, but the combination of regulatory opacity, infrastructure risk and fragmented distribution raises the capital risk premium for scaling health solutions.</p><p><strong>Adoption &amp; localization.</strong> Operators emphasized that adoption hinges on localization (offline-first, language, USSD). Kenya and South Africa show higher levels of digital literacy and more familiarity with digital services — Kenya in particular benefits from a mobile-money culture that lowered the mental cost of digital adoption. Nigeria’s diversity and lower average digital literacy make localization crucial; several founders said that offline-first and pharmacy/community-agent models are the most effective GTM levers in Nigeria.</p><blockquote>When it comes to digital health scalability, I’d argue Kenya and possibly Egypt are leading the way. Kenya benefits from strong mobile money rails and a culture of tech adoption, while Egypt has scale and growing private-sector investment. South Africa is slowed down by regulatory red tape, and Nigeria’s size, while an opportunity, also makes coordinated scaling very complex. — <a href="https://www.linkedin.com/in/tomachoki/">Tom Achoki</a>, <a href="https://africahealthpolicy.org/">Africa Institute for Health Policy</a></blockquote><p><strong>How to read these differences (practical implications).</strong></p><ul><li>South Africa: best for large-scale, hospital/IoMT and insurer-backed deployments because policy, infrastructure and payers line up. If you’re building high-complexity hospital software or IoMT devices that need robust backhaul and regulated reimbursement, South Africa is the highest-probability market.</li><li>Kenya: the most pragmatic “digital testbed” for interoperable, mobile-first solutions. Kenya’s policy agility, mobile-money norms, and openness to standards make it ideal for products that need to prove national public-sector integration (e.g., FHIR, claims APIs, telemedicine reimbursement pilots).</li><li>Nigeria: the largest market and the most diverse set of commercial opportunities, but also the most conditional market. Success requires (a) infrastructure-aware product design (offline-first, USSD), (b) GTM that embeds into trusted local channels (pharmacies, community health agents, insurers, telcos), and © financing strategies built on blended capital and PPPs rather than consumer payments alone.</li></ul><p>Bottom line / recommendation for Nigeria. Respondents’ views converge on a clear roadmap: Nigeria will scale when three gaps are closed in parallel: policy harmonization (clearer NHIA/NPHCDA rules and sandboxes), reliable data/identity rails (interoperability + NIN linkage), and localized distribution (pharmacies, CHWs, telco/agent partnerships). The country’s advantages — large population, many entrepreneurial teams, and numerous pilots — become strengths only if these three enablers are activated. Kenya and South Africa show two plausible shortcuts: Kenya’s standards and mobile culture accelerate public integrations; South Africa’s payer/infrastructure depth supports capital-intensive hospital and IoMT plays. Nigeria should borrow both playbooks: push for interoperable standards and mobile-first flows (Kenya), while accelerating payer coverage and large public sector pilots to create investable scale (South Africa).</p><h3>F. Exit Math &amp; M&amp;A Archetypes</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*D0yCQFBlJQO4sPeigJamqA.png" /><figcaption><strong>VCs Investing in Nigerian Health tech</strong> PS: This is not an exhaustive list. Please reach out via <a href="https://www.linkedin.com/in/isaac-ekundayo/">LinkedIn</a> if your fund wasn’t highlighted</figcaption></figure><p>Exits in African healthtech rarely follow the Silicon Valley template of rapid unicorn IPOs. Instead, the pathways reflect the continent’s healthcare realities: fragmented supply chains, donor dependence, and infrastructure deficits. Investors and ecosystem leaders point to four dominant archetypes shaping mergers, acquisitions (M&amp;A), and liquidity events across Africa: corporate acquisitions, private equity roll-ups, blended finance transitions, and secondaries.</p><p><strong>1. Corporate acquisitions as the center of gravity.</strong></p><p>Corporate acquisitions remain the most realistic and common exit pathway. Telcos, insurers, and pharmaceutical distributors increasingly turn to healthtech startups to plug gaps in claims processing, pharmacy supply chains, or patient engagement. Startups like Reliance Health, which began as Kangpe telemedicine and pivoted into an HMO, illustrate this trajectory, solving the deeper supply and financing bottlenecks that made them attractive to larger partners. One investor explained, “B2B<em> remains the most liquid segment in the African market. Infrastructure financing is essential for clinics and health facilities to scale and fill the strong apparent local need, although this requires patient capital.”</em></p><p><strong>2. Private equity roll-ups and consolidation.<br></strong>The fragmented nature of healthcare creates strong opportunities for roll-ups; PE-backed strategies to consolidate smaller players into stronger platforms that can negotiate with governments, insurers, and multinational pharma companies. EMRs, health data platforms, and pharmacy distribution networks are prime candidates. As another investor noted, <em>“Microtransactions only work with volume. So, healthtech startups need the quickest path to massive adoption; this is where telco partnerships could work. Churches are another angle that’s yet to be explored.”</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/220/1*4IzrLU-VRbKaqOJU0mXqwA.gif" /></figure><p><strong>3. Blended finance and donor-to-commercial transitions.<br></strong>Donor pilots often provide early traction but rarely scale, creating what investors describe as “pilot fatigue.” To transition from grants to sustainability, blended finance (mixing DFIs, private VC, and corporates) is emerging as a critical mechanism. These models often culminate in acquisitions by corporates or government-backed PPPs once unit economics are proven. As <a href="https://www.linkedin.com/in/obianujundedigwe/?originalSubdomain=ng">Obianuju Ndedigwe</a>, formerly of <a href="https://healthcap.co/">HealthCap</a>, observed, “To<em> mitigate infrastructure risks, design products that work with what’s available — low bandwidth, USSD, offline modes, and basic smartphones. For pilot fatigue, avoid short-term, donor-driven pilots. Instead, build with clear pathways to scale: involve governments or large health systems early, prove unit economics quickly, and show how your solution integrates into existing workflows.”</em></p><p><strong>4. Secondaries as a bridge to patient capital.<br></strong>In Nigeria and Kenya, where startups are scaling but IPOs remain unlikely, secondaries, early investors selling stakes to larger DFIs or PE firms, are becoming a key liquidity mechanism. This archetype is most viable for B2B SaaS and health-financing platforms with recurring revenue. It allows early-stage VCs to exit while later-stage funds with longer time horizons provide the capital needed to push startups toward market consolidation or acquisition.</p><p><strong>5. IPOs remain aspirational.<br></strong>Despite fintech players like Interswitch and Flutterwave pushing IPO narratives, healthtech is still far behind. Lower margins, heavier infrastructure dependencies, and complex regulation make IPOs an aspirational goal rather than a realistic near-term pathway. For now, public markets are unlikely to play a significant role in healthtech exits.</p><h3>G. Investor Theses Emerging</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1023/1*kcp9bzN8dW_3D04SlADY0w.jpeg" /><figcaption>investor vibes :)</figcaption></figure><p>The African healthtech investment thesis is diverging from the Silicon Valley playbook, shaped instead by local infrastructure realities, fragmented health systems, and patient capital requirements. Across investors and incubators, four consistent themes emerge: commercial viability, infrastructure-first design, blended finance pathways, and systemic alignment.</p><p><strong>1. Commercial viability and impact over hype</strong></p><p><a href="https://www.linkedin.com/in/stephanie-okpere-mph-prince2%C2%AE-85193975?originalSubdomain=ng">Stephanie Okpere</a> of <a href="https://cchub.africa/">Cocreation Hub</a> emphasizes that healthtech in Africa cannot rely on scale for scale’s sake but must combine financial sustainability with impact. <em>“The Africa investment landscape is thoroughly different from the Silicon Valley approach. Here, there are several factors to consider, and the focus should be to (1) have a commercially viable, scalable, and impact-focused solution and (2) also seek investment in local currency. Investment in foreign currency may not always be the best. Local inflation will determine how much effort may be required to make profit on the investment”</em> (Okpere, CcHub).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Y7W3f75G-Qs6VYnPcJfeBw.png" /><figcaption><em>Also seek investment in local currency — Stephanie Okpere</em></figcaption></figure><p>Other investors echoed this emphasis on patient, impact-oriented capital, highlighting that poor valuations, non–user-centric products, and lack of scalability often keep even investment-ready startups from finding suitable matches.</p><p><strong>2. Infrastructure-first, monetization later</strong></p><p>Several investors highlighted the primacy of infrastructure building as a precondition for scale. <a href="https://www.linkedin.com/in/obianujundedigwe/?originalSubdomain=ng">Obianuju Ndedigwe</a>, formerly of <a href="https://healthcap.co/">HealthCap Africa</a>, explained that the biggest monetization opportunities lie where technology solves bottlenecks: <em>“Top areas will be B2B health infrastructure platforms, health financing and insurance tech, and digital pharma and last-mile distribution.”</em> She further argued that trust, infrastructure backbones like EMRs and inventory systems, and indirect monetization through insurers and employers will define sustainable growth.</p><p>Another investor who asked to be anonymous framed it succinctly: <em>“Infrastructure first, monetization next. It all takes time,, but in the end it compounds.” </em>Products must be designed for real-world constraints. As one accelerator leader put it, “Infrastructure<em> deficits, pilot fatigue, and limited exits remain the biggest risks. To mitigate, design for low-bandwidth, USSD, offline-first, and basic smartphones. Don’t assume internet or electricity will be consistent.”</em></p><p>This echoes lessons from fintech, where payment rails laid the foundation for later consumer-facing apps. For healthtech, the rails will be interoperable EMRs, inventory systems, claims processing APIs, and pharmacy networks.</p><p><strong>3. Blended finance and pragmatic exits</strong></p><p>Investors broadly see blended finance models, mixing donor grants, DFIs, impact investors, and VC, as the most realistic path to de-risk early innovation before commercial capital steps in. This thesis also ties into exit archetypes: corporate acquisitions, PE roll-ups, and secondaries are seen as more likely than IPOs in the near term.</p><p><strong>4. Systemic alignment and emerging tech layers</strong></p><p>An anonymous investor notes the role of AI and IoMT as supportive, not standalone layers: <em>“AI comes with huge savings in labor and knowledge… IoMTs are already winning, with examples in Oraimo and white-label wearables flooding the market. However, this is a capital-intensive market for which a VC play might not be the best model. What might work is building a lower-tech device for a poorer market segment. This has market-creating potential.”</em></p><p>Obianuju also highlighted the role of mobile-first approaches, stressing that Africa’s 650M+ mobile subscribers and rising smartphone penetration remain one of the continent’s most powerful healthcare infrastructures. But she cautions that solutions must build on existing behaviors, such as pharmacies and informal providers, just as mobile money built on cash habits.</p><blockquote>“The biggest role of AI, IoMT, and mobile-first solutions will be in lowering the cost of experimentation. They’ll make it easier to test hypotheses quickly, build MVPs, and validate what really works in African healthcare before scaling.” — <a href="https://www.linkedin.com/in/ayodeji-s-alaran/">Ayodeji Alaran</a>, CEO, P<a href="https://pbrinsight.com/">BR Life Sciences</a></blockquote><p><strong>5. The unifying thread: health system bottlenecks</strong></p><p>Across perspectives, one investor summed up the constraint starkly: <em>“When we tear African healthcare down to base reality, the most fundamental problem is supply — of health workers, services, facilities, and reliable drugs. While it is possible to build mobile-first solutions in the face of this, it will always be a drag on the success of said solutions.”</em></p><p>Thus, investor theses converge on a systems lens: healthtech that integrates into and strengthens existing delivery systems, rather than trying to disrupt them outright, will be more attractive to funders and more likely to achieve sustainable exits.</p><h3>H. Risk Mitigation in African Healthtech</h3><p>Despite the growing appetite for healthtech on the continent, investors consistently identify three major risks: infrastructure deficits, pilot fatigue, and limited exit opportunities. Mitigating these risks requires a mix of pragmatic product design, blended finance strategies, and deeper integration with health systems.</p><p><strong>1. Infrastructure deficits</strong><br>The lack of reliable electricity, broadband connectivity, and health system backbones such as electronic medical records makes scaling digital health solutions extremely difficult. Investors emphasize that startups must <em>design for the infrastructure that exists rather than the one they wish for.</em></p><p>This mirrors the fintech playbook. Nigerian fintechs like Paga, OPay, and others achieved mass adoption not by waiting for internet penetration to improve but by leveraging USSD codes, agent networks, and SMS-based transactions. These tools allowed financial inclusion to leapfrog infrastructure gaps. Healthtech can adopt the same “offline-first” mindset, ensuring solutions work under poor connectivity conditions while still offering digital value.</p><p><strong>2. Pilot fatigue</strong></p><p>Donor-driven pilots often generate early enthusiasm but fail to scale beyond the initial funding window. This has created “pilot fatigue” among governments, communities, and even investors who have seen too many promising ideas stall. To counter this, investors recommend designing pilots with clear pathways to scale from the outset. This involves involving governments or large health systems early in the process, proving unit economics quickly, and ensuring that solutions integrate into existing workflows rather than working in silos.</p><p>Fintech faced a parallel challenge in its early days. Banks and regulators were skeptical of mobile payments, and initial pilots sometimes failed to build trust. The turning point came when fintech companies partnered with telcos, governments, and regulators to integrate into national payment rails. For healthtech, similar partnerships — with ministries of health, insurance schemes, and large hospital systems — will be critical to avoid pilot fatigue and build sustainable adoption.</p><p><strong>3. Limited exits</strong></p><p>Another challenge is the lack of clear exit pathways for investors in African healthtech. IPOs remain unrealistic in the short term, and acquisition appetite is still emerging. To mitigate this, investors are focusing on startups with sustainable revenue models and solutions that can be streamlined for broader market adoption. As one investor put it, <em>“Streamlining healthcare products to a sizeable market”</em> improves attractiveness to corporates and PE firms, increasing the chances of M&amp;A activity. Others suggest prioritizing startups that take advantage of knowledge and labor cost savings from AI, which can achieve quicker profitability and therefore offer better exit opportunities.</p><p>Here too, fintech offers a lesson. Early Nigerian fintech startups built scale-first models with clear monetization through transaction fees, leading to multiple acquisitions and secondary exits once user bases grew. For healthtech, exits are more likely to occur through corporate acquisitions (e.g., large hospital groups, insurers, or pharmaceutical distributors) rather than IPOs. Structuring for this reality from the start is key.</p><h3><strong>Conclusion</strong></h3><p>Nigeria’s healthtech is at a familiar inflection, mirroring fintech’s 2015–2017 moment but demanding a more nuanced playbook. The winners here won’t be those chasing vanity metrics or direct-to-consumer scale; they will be those who build infrastructure moats, structure blended capital intelligently, and align early with public-private financing rails.</p><p>The smart capital will move first; not just with equity, but with catalytic grants, RBF pilots, and patient secondary structures that de-risk infrastructure-heavy bets while preserving upside for expansion. Regulation will catch up as it did in fintech, but the arbitrage window is now: investors who underwrite this transition from grant dependence to scalable, PPP-backed models will own the rails on which HealthTech 2.0 compounds.</p><p>This is not a consumer app play. It is a systemic rewiring of Nigeria’s health economy, and the capital that understands that will capture both outsized returns and enduring impact.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*fEO2G3XmGghFGMfgsyHsIg.jpeg" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=97d220597a00" width="1" height="1" alt=""><hr><p><a href="https://medium.com/included-vc/could-nigerias-healthtech-be-in-its-fintech-2015-2017-era-97d220597a00">Could Nigeria’s HealthTech Be in Its Fintech 2015–2017 Era?</a> was originally published in <a href="https://medium.com/included-vc">Included VC</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>